Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2009 Oct 15.
Published in final edited form as: Neuroscientist. 2009 Mar 26;15(5):549–567. doi: 10.1177/1073858409333075

The State of Synapses in Fragile X Syndrome

Brad E Pfeiffer 1, Kimberly M Huber 1
PMCID: PMC2762019  NIHMSID: NIHMS127816  PMID: 19325170

Abstract

Fragile X Syndrome is the most common inherited form of mental retardation and a leading genetic cause of autism. There is increasing evidence in both FXS and other forms of autism that alterations in synapse number, structure and function are associated and contribute to these prevalent diseases. FXS is caused by loss of function of the Fmr1 gene which encodes the RNA binding protein, FMRP. Therefore, FXS is a tractable model to understand synaptic dysfunction in cognitive disorders. FMRP is present at synapses where it associates with mRNA and polyribosomes. Accumulating evidence finds roles for FMRP in synapse development, elimination and plasticity. Here, we review the synaptic changes observed in FXS and try to relate these changes to what is known about the molecular function of FMRP. Recent advances in the understanding of the molecular and synaptic function of FMRP, as well as the consequences of its loss, have led to the development of novel therapeutic strategies for FXS and related diseases such as autism.

Fragile X Syndrome

In the United States, the prevalence of mental retardation and autism has been estimated at approximately 0.78% of the population (Larson et al., 2001). Although the social impact of these complex diseases is immeasurable, the lifetime economic cost for all mentally retarded individuals born in the U.S. in the year 2000 has been calculated at over $50 billion (Honeycutt et al., 2004) underscoring the importance for scientific research on the root causes of mental retardation and autism.

The most common form of inherited mental retardation is Fragile X Syndrome (FXS), and affects approximately 1:4000 males and 1:8000 females (O’Donnell and Warren, 2002). Though the severity and manifestation of symptoms of the disease varies, FXS has several common phenotypes: in addition to a reduction in intellectual ability or IQ, which ranges from mild to severe, many FXS patients also display hyperactivity, hypersensitivity to sensory stimuli, anxiety, impaired visuo-spatial processing, and developmental delay. Thirty percent of children with FXS are diagnosed with autism and 2–5% of autistic children have FXS (Kau et al., 2004; Hagerman et al., 2005). In recent years, a number of human genes have been linked to autism, with FMR1 being one of the most commonly linked (Kaufmann et al., 2004; Hagerman et al., 2005). Furthermore, roughly 25% of FXS patients suffer from epilepsy (Kaufmann et al., 2004; Hagerman et al., 2005), making FXS a leading genetic model of several complex diseases.

Loss of function of the Fragile X Mental Retardation Gene (FMR1) causes Fragile X Syndrome

The molecular cause of FXS arises from loss-of-function mutations in the X-chromosome gene, FMR1 (reviewed in (O’Donnell and Warren, 2002; Garber et al., 2006)). In nearly all cases, the observed mutation is an expansion of a CGG trinucleotide repeat in the promoter region of the gene. In unaffected individuals, the CGG region is repeated 5 to 50 times. Individuals harboring between 50–200 CGG repeats are defined as premutation carriers. The full mutation state is defined as greater than 200 CGG repeats. At this size, hypermethylation of the repeat region leads to the transcriptional silencing of the FMR1 gene, and loss of the protein product of FMR1, Fragile X Mental Retardation protein (FMRP), an RNA binding protein. Furthermore, intragenic loss-of-function point mutations or deletions also lead to Fragile X Syndrome (De Boulle et al., 1993; Lugenbeel et al., 1995). Thus, it is widely accepted that FXS results from the loss or significant reduction of FMRP function. In support of this view, the phenotypic variation in IQ and physical features of FXS patients is strongly correlated with levels of FMRP in the blood (Tassone et al., 1999; Loesch et al., 2002; Loesch et al., 2003; Loesch et al., 2004). A mouse model of the disease was created by inserting a neomycin cassette into exon 5 of the mouse Fmr1 gene (Bakker, 1994). Although, it is difficult to model human mental retardation in mice, the Fmr1 knockout (KO) mouse recapitulates many aspects of the human FXS condition, including hyperactivity, macroorchidism, anxiety and deficits in learning and memory (Bakker, 1994; Paradee et al., 1999; Spencer et al., 2005; Brennan et al., 2006). The Fmr1 KO mouse model has been instrumental in studies designed to understand the neurobiological underpinnings of FXS, as well as test new treatment strategies for the condition.

Current models regarding the neurobiological changes which underlie FXS are focused on the synapse. This is based in part on the structural synaptic changes which are observed in both human patients and Fmr1 KO mouse, as well as alterations in synaptic function observed in the mouse model. Furthermore, recent elucidation of the molecular and cellular functions of FMRP has led researchers to the synapse. Therefore, this review will focus on describing the alterations in synaptic structure, function and plasticity of synapses in FXS and we propose potential cellular mechanisms for these changes based on the known functions of FMRP. There have been several excellent recent reviews on the genetics and clinical features of Fragile X Syndrome or molecular functions of FMRP (Bear, 2005; Garber et al., 2006; Penagarikano et al., 2007; Bassell and Warren, 2008).

Fragile X Mental Retardation Protein: A regulator of dendritic protein synthesis?

To understand the etiology of the synaptic phenotypes which accompany FXS, it is first important to discuss the purported function of FMRP. FMRP is an RNA binding protein whose primary function is thought to be regulation of mRNA translation and perhaps transport of mRNA into dendrites (reviewed by (Feng, 2002; Garber et al., 2006; Bassell and Warren, 2008). FMRP is found in nearly all cell types of the body, and is expressed particularly strongly in neurons, with minimal expression in glia (Feng et al., 1997a). Although FMRP has functional nuclear localization and export elements, FMRP is primarily found in the cytoplasm (95%) where it is localized to the soma, dendrites, and post-synapse (Eberhart et al., 1996; Feng et al., 1997a; Bakker et al., 2000; Antar et al., 2004). FMRP has also been observed in both axonal growth cones and some mature axons (Antar et al., 2006; Price et al., 2006). Consequently, there is evidence that FMRP may regulate growth cone guidance and/or presynaptic function (Pan et al., 2004; Antar et al., 2006; Hanson and Madison, 2007).

FMRP is an RNA binding protein

FMRP interacts with RNA through several RNA-binding motifs, two hnRNP-K homology domains (KH domains, KH1 and KH2), an arginine/glycine-rich RNA-binding motif (RGG box) and a recently discovered N-terminal domain of FMRP (NDF) (Ashley et al., 1993; Gibson et al., 1993; Siomi et al., 1993; Adinolfi et al., 2003; Zalfa et al., 2005). The KH2 domain is particularly interesting because a single site mutation in the KH2 domain (an isoleucine to asparagine substitution at residue 304; I304N) in FMRP results in a severe form of Fragile X Syndrome in one patient (De Boulle et al., 1993). In addition to disrupting interaction with “kissing complex” RNA structures, I304N FMRP no longer associates with polyribosomes or regulates translation (Feng et al., 1997b; Laggerbauer et al., 2001; Darnell et al., 2005b). These results suggest that disruption of FMRP-RNA interactions or regulation leads to Fragile X Syndrome. FMRP is thought to bind to as many as 400–600 different brain mRNAs, including its own message (Brown et al., 2001; O’Donnell and Warren, 2002) and associates with large, translating polyribosome complexes in brain in an RNA-dependent manner (Khandjian et al., 1996; Tamanini et al., 1996; Feng et al., 1997b; Feng et al., 1997a; Khandjian et al., 2004; Stefani et al., 2004). FMRP is associated with polyribosomes throughout neurons, including dendrites and spines and may be particularly important for translational regulation of dendritic mRNAs (Feng et al., 1997a; Antar et al., 2004). FMRP is also present in smaller mRNA ribonucleoprotein complexes (mRNP) and dendritic “RNA granules,” which are thought to be translationally arrested complexes of ribosomes, RNA-binding proteins, and RNAs, which travel to dendrites on microtubules (Kanai et al., 2004; Antar et al., 2005). Interestingly, FMRP may shuttle between the mRNP and polyribosomes depending on the translational state of the cell (Vasudevan and Steitz, 2007; Wang et al., 2007). It is therefore thought that FMRP may play a role in the local regulation of protein expression at individual synapses remote from the cell body (Fig. 1) (Bassell and Warren, 2008; Ronesi and Huber, 2008a).

Figure 1. FMRP regulation of mRNA transport and local translation impacts synaptic structure and function.

Figure 1

FMRP is shuttles to and from the nucleus where it may play a role in nuclear export of mRNAs. FMRP is found both in growth cones, immature axons and mature dendrites, as well as dendritic spines. In these compartments, FMRP is associated with mRNPs and larger RNA granule structures which also contain FMRP-interacting proteins such as FXRs and CYFIP. RNA granules and FMRP travel into dendrites via kinesin motors on microtubules. During transport, it is thought that FMRP functions to translationally suppress cargo mRNAs. Inset: Once in the spine FMRP phosphorylation and ubiquitination are regulated by mGluR activity which is thought to play a role is activation of translation initiation and elongation. Proteins whose translation is regulated by FMRP include Arc and MAP1b, all of which are known to regulate AMPA receptor endocytosis and thereby synaptic function.

Due to the fact that FMRP is an RNA binding protein, a key to understanding how FMRP regulates the nervous system and the effects of FMRP loss is the identity of the relevant mRNA targets. Many studies have identified interacting mRNAs of FMRP using different methods (Sung et al., 2000; Brown et al., 2001; Darnell et al., 2001; Dolzhanskaya et al., 2003; Miyashiro et al., 2003; Zalfa et al., 2003). However, only a handful of mRNAs have been validated as in vivo FMRP targets or shown to be misregulated in Fmr1 KO mice (reviewed in (Darnell et al., 2005a; Bassell and Warren, 2008). Of particular interest are FMRP target mRNAs which are present in the dendrite and may play a role in the postsynaptic regulation by FMRP. Some of these include the Fmr1 mRNA itself, microtubule associated protein 1b (MAP1b), postsynaptic density protein 95kDa (PSD-95), activity-regulated cytoskeletal protein (Arc), amyloid precursor protein (APP), elongation factor 1a (EF1a), AMPA Receptor subunits GluR1 and 2, and α Ca2+/Calmodulin-dependent kinase II (Brown et al., 2001; Darnell et al., 2001; Sung et al., 2003; Todd et al., 2003; Lu et al., 2004; Hou et al., 2006; Muddashetty et al., 2007; Zalfa et al., 2007; Bassell and Warren, 2008; Liao et al., 2008). Although yet to be validated, numerous additional mRNAs for synaptic proteins, both pre- and postsynaptic, have been identified as putative mRNA targets, suggesting that FMRP may regulate synaptic structure and function through processing, localization or translational regulation of mRNAs encoding pre- and postsynaptic proteins (Brown et al., 2001; Darnell et al., 2001; Miyashiro et al., 2003).

Recent works finds a role for FMRP in the dendritic transport of its mRNA targets (reviewed in (Bassell and Warren, 2008) (Fig. 1). FMRP and associated mRNAs are co-transported into dendrites under basal conditions and in response to neuronal activity (Antar et al., 2004; Antar et al., 2005). Without FMRP, steady state levels of dendritic mRNAs are normal, but RNA granules are less motile and there is a deficit in activity-dependent dendritic mRNA transport in cultured Fmr1 KO hippocampal neurons or the Fragile X fly model (Dictenberg et al., 2008; Estes et al., 2008). Dictenberg et al., (2008) identified a C-terminal portion of FMRP that interacts with kinesin light chain (KLC) and expression of this FMRP C-term competes with endogenous FMRP for binding to KLC and blocks transport of FMRP target mRNAs into dendrites (Davidovic et al., 2007; Dictenberg et al., 2008). FMRP association with its targets may also function to stabilize some mRNA targets, such as that for PSD-95 (Zalfa et al., 2007).

Exactly how FMRP regulates translation of its mRNA targets is not entirely understood, but there is evidence that FMRP may act as both a translational suppressor and activator. FMRP-mediated translational suppression of mRNAs in granules is likely important to avoid inappropriate expression of proteins during transport into dendrites (Kindler et al., 2005; Wells, 2006). Evidence for FMRP as a translational suppressor comes from both in vitro translation assays and in vivo experiments in Fmr1 KO mice (Laggerbauer et al., 2001; Li et al., 2001; Qin et al., 2005a). The brains of Fmr1 KO mice exhibit increased protein synthesis rates and an increased association of dendritic mRNAs, such as PSD-95, Arc and GluR1 with translating polyribosomes in comparison to wild-type mouse brains (Qin et al., 2005a; Hou et al., 2006; Muddashetty et al., 2007; Zalfa et al., 2007). One proposed mechanism for FMRP-mediated translational suppression is through association with short noncoding RNAs or microRNAs (miRNAs) which suppress translation by base-pairing with partially complementary mRNA sequences and interaction with proteins in the RNA-induced silencing complex (RISC). The Argonaut proteins, which are a part of the RISC, associate with FMRP, further supporting that FMRP suppresses translation through miRNAs and a RISC-dependent mechanism (Caudy et al., 2002; Jin et al., 2004). Identity of the specific miRNAs that interact with FMRP is unknown. Recent work provides mechanistic insight into how FMRP suppresses the translation machinery. FMRP interacts with Cytoplasmic FMRP-interacting protein (CYFIP1), which in turn binds to the 5′ cap binding protein eIF4E, and prevents formation of the eIF4F initiation complex (Schenck et al., 2001; Napoli et al., 2008).

Once mRNAs reach their dendritic destination, FMRP may also facilitate their translation in response to synaptic activity. In support of this hypothesis, a fraction of FMRP is associated with translating polyribosomes in brain and protein synthesis in response to activation of group 1 metabotropic glutamate receptors (mGluRs) is absent in the Fmr1 KO mice (Feng et al., 1997a; Todd et al., 2003; Khandjian et al., 2004; Stefani et al., 2004; Weiler et al., 2004; Hou et al., 2006; Ronesi and Huber, 2008b) (Fig. 1). Consequently, mGluR dependent plasticity of synaptic and neuronal function is altered in Fmr1 KO mice (Huber et al., 2002; Koekkoek et al., 2005; Hou et al., 2006). The role of FMRP in mGluR stimulated protein synthesis and plasticity will be discussed in the context of synaptic plasticity below.

Fragile X Syndrome: A defectin synapse elimination?

Human studies

Some of the first neuroanatomical findings associated with mental retardation were alterations in dendritic spine structure (Marin-Padilla, 1972; Purpura, 1974). Dendritic spines are the point of excitatory postsynaptic contact suggesting alterations in synaptic function, strength or development underlie the cognitive dysfunction. Alterations in dendritic spine number, shape and size are common among cognitive disorders, including FXS, Rett’s and Down Syndromes (Kaufmann and Moser, 2000).

The first such evidence of altered synapse structure in FXS came from analysis of post-mortem cortical tissue, which revealed an increased number of dendritic spines relative to control individuals (Rudelli et al., 1985; Hinton et al., 1991; Wisniewski et al., 1991; Irwin et al., 2001). These data suggested that excitatory synapse number was increased in FXS patients and further provided a potential mechanism for the increased rates of epilepsy in FXS. It was additionally noted that a large proportion of the spines of FXS patients appeared abnormally long, thin, and tortuous, a phenotype reminiscent of the immature spine precursors, filopodia, and indicative of alterations in synapse development and/or function (Fiala et al., 1998). It is still not clear if the excess filopodia-like spines in FXS represent functional synapses or immature synapse precursors.

Fragile X Syndrome mouse model studies

Work in the Fmr1 KO mouse has largely confirmed the spine phenotype observed in FXS patients (Nimchinsky et al., 2001; Irwin et al., 2002; Galvez and Greenough, 2005; McKinney et al., 2005). However, the existence and/or magnitude of the spine alterations in the Fmr1 KO mouse varies according to brain region, developmental age and genetic background indicating the complex and multi-factorial regulation of spines. Several studies agree that there is an increase in spine number in mature neocortical neurons, but this appears to be sensitive to genetic background (Irwin et al., 2002). The C57Bl6 mouse strain of Fmr1 KO best recapitulates the human spine differences because adult neocortical neurons (both layer 2/3 and layer 5) display increased spine number, as well as spine length (Galvez and Greenough, 2005; McKinney et al., 2005; Dolen et al., 2007; Hayashi et al., 2007) (Fig. 3). There also appears to be a developmental regulation of the spine phenotype. In very young neurons (1 week postnatal) there is an increased spine density, as well as longer spines in somatosensory layer 5 pyramidal neurons of the FVB strain of Fmr1 KO mice in comparison to wildtype mice. The dendritic spine alterations are absent in adolescent mice, but reappear in the adult (Nimchinsky et al., 2001; Galvez and Greenough, 2005). Indeed other studies have reported the elongated spines in adolescent or adult neocortex, with no increase in spine density (Restivo et al., 2005; Meredith et al., 2007).

Figure 3. Alterations in synaptic structure, function and plasticity in sensory neocortex of Fmr1 KO mice.

Figure 3

Schematic summarizing major synaptic alterations in sensory neocortex: Size of arrows indicate the magnitude and direction of change. 1) A reduction in the synaptic connectivity of layer (L) 4 excitatory (Ex) neurons with neighboring L4 excitatory neurons, fast spiking (FS) inhibitory interneurons and L2/3 pyramidal neurons. 2) Increase in dendritic spine density and length of layer 2/3 and 5 neurons, although to date no functional change in synapse number has been demonstrated. 3) A reduced threshold for LTP in L2/3 and 5 synapses. 4) Increased L4 axonal length and spread into L2/3. In addition to synaptic changes, increases in intrinsic excitability are observed in L4 excitatory neurons. Overall, there is a circuit hyperexcitability in response to thalamic stimulation in sensory neocortex which may be mediated by the reduction in excitatory drive onto L4 FS inhibitory neurons, the increase in intrinsic excitability of L4 excitatory neurons and the increase in spine density on pyramidal neurons in L2/3 and 5.

Several studies have observed an increase in the number of long, thin spines and a decreased number of short, stubby spines on neocortical neurons in Fmr1 KO mice (Irwin et al., 2002; McKinney et al., 2005; Restivo et al., 2005; Meredith et al., 2007). In contrast to neocortex, mature CA1 hippocampal Fmr1 KO neurons in vivo possess more stubby spines and fewer long, thin spines with no change in spine density (Grossman et al., 2006). Stubby spines with large heads are associated with increased synaptic strength (Matsuzaki et al., 2001; Okabe et al., 2001; Kopec et al., 2006), suggesting that CA1 neurons of Fmr1 KO mice have increased excitatory drive similar to neocortical neurons with excess spine density.

How might the absence of FMRP lead to altered spine number and structure? FMRP may regulate synapse formation, maintenance and/or elimination. Currently it is unclear which process (or processes) FMRP regulates. It has been hypothesized that the absence of FMRP leads to a deficit in synaptic pruning, resulting in an overabundance of synapses (Weiler and Greenough, 1999; Bagni and Greenough, 2005; Antar et al., 2006). Early neocortical synapse development is characterized by an excess production of synaptic connections (Rakic et al., 1986; Markus and Petit, 1987; Grutzendler et al., 2002; Zuo et al., 2005a; Zuo et al., 2005b). During adolescence, an elimination, or pruning, of spines or synapses occurs which requires sensory experience (Zuo et al., 2005b). Additional studies implicate FMRP in larger scale, dendritic pruning. In the mouse somatosensory barrel cortex, immature spiny stellate cells extend their dendrites into both the hollow and septa of the cortical “barrels.” During development, septal-oriented protrusions are normally eliminated; however, Fmr1 KO mice display a failure to prune these septal-oriented dendrites (Galvez et al., 2003). It is important to note, however, that the developmental pruning of multiply-innervated climbing fiber/Purkinje cell connections to singly-innervated connections appears to be normal or even slightly accelerated in Fmr1 KO mice (Koekkoek et al., 2005). It is therefore possible that FMRP may have a region- or cell type-specific role in postsynaptic pruning mechanisms.

Although the lifelong loss of FMRP in humans and mice results in altered dendritic spines, it was unknown if FMRP directly regulated synapse number, function, or maturation in a cell autonomous fashion. Recent work demonstrated that acute, postsynaptic expression of FMRP negatively regulates synapse number in hippocampal pyramidal neurons (Pfeiffer and Huber, 2007) (Fig. 2). Developing hippocampal Fmr1 KO neurons in culture display increased synapses, as assessed by immunocytochemical markers. Acute expression of FMRP in Fmr1 KO neurons resulted in a loss of synapses at both the functional and structural level. Interestingly, measures of functional synapse maturation, such as NMDA receptor properties or the percent of “silent” synapses, were not affected by acute FMRP expression. Furthermore, synapse elimination was not seen following expression of single point-mutant forms of FMRP, such as I304N or one which mimics phosphorylation at the Ser500 residue, S500D (Pfeiffer and Huber, 2007). The latter indicates that postsynaptic FMRP interactions with translating polyribosomes are important for FMRP regulation of synapse number. Expression of the C-terminus of FMRP, which contains the KLC binding domain and blocks dendritic transport of FMRP target mRNAs, results in an increase in the number and length of dendritic filopodia, precursors to synapses, suggestive of a role for dendritic mRNA and translation in this process (Dictenberg et al., 2008).

Figure 2. Evidence for a direct, postsynaptic role of FMRP in synapse elimination.

Figure 2

A Cultured Fmr1 KO hippocampal neurons (equivalent postnatal day 12–16) have more structural synapses. Top Left, Mixed dissociated culture prepared from both wild-type and Fmr1-KO mice labeled with an antibody against FMRP (green fluorescence) and the synaptic marker GluR1 (red fluorescence) (scale 10 μm). Bottom Left, High resolution image of highlighted sections in top left panel (scale = 5 μm). Right, Quantification of the number of synaptic puncta on Fmr1-KO neurons and neighboring WT neurons for three synaptic markers: surface GluR1, PSD-95, and synapsin. B. Acute postsynaptic expression of FMRP results in fewer functional synapses. Top, Depiction of experimental paradigm in which organotypic hippocampal slice cultures are prepared from Fmr1-KO mice and biolistically transfected with GFP-tagged FMRP. Simultaneous whole cell recordings are then obtained from untransfected Fmr1 KO (FMRP lacking) and FMRP-expressing neurons to quantify electrophysiological changes. Middle, Representative traces for evoked NMDA receptor-mediated synaptic responses (upper left, scale 20 pA, 20 ms), AMPA receptor-mediated synaptic responses (lower left, scale 20 pA, 20 ms), and miniature EPSCs (right, scale 10 pA, 500 ms). Traces from FMRP-expressing (transfected) neurons are shown in grey and those from FMRP-lacking (untransfected) neurons are shown in black. Bottom, Quantification of synaptic function following FMRP expression in Fmr1-KO neurons for evoked AMPA receptor-mediated responses, evoked NMDAR-mediated responses, miniature EPSC frequency and amplitude, and synaptic failure rate. *p-value < 0.05, **p-value < 0.01, ***p-value < 0.001. Modified with permission from (Pfeiffer and Huber, 2007).

Evidence for a pruning function for Drosophila FMRP (dFXR)

Much of the evidence for a role for FMRP in synaptic and neurite pruning comes from the Drosophila melongaster model of Fragile X Syndrome. In mammals, FMRP has two autosomal homologs, Fragile X Related Proteins 1 and 2 (FXR1 and FXR2), which share ~60% amino acid identity (Hoogeveen et al., 2002) and likely function similarly to FMRP, in that they have similar RNA binding motifs and associate with FMRP in RNA granules (Bakker et al., 2000; De Diego Otero et al., 2002; Kanai et al., 2004). In Drosophila, Fragile X Related Protein (dFXR), is thought to serve the function of mammalian FMRP and FXRs (Zarnescu et al., 2005). Consequently, the phenotypes observed in the dFXR-mutant Drosophila lines, are typically more severe or even different from the mouse and human phenotypes.

In support of a pruning function for dFXR, most neurons of dFXR null flies exhibit an overgrowth and elaboration of axons and dendrites in both the peripheral and central nervous system (Zhang et al., 2001; Gao, 2002; Morales et al., 2002; Lee et al., 2003; Pan et al., 2004; Zhang and Broadie, 2005). The neuromuscular junction (NMJ) has been most well characterized where in addition to increased axon branching and presynaptic bouton number there is enhanced synaptic function consistent with an increase in presynaptic neurotransmitter release and/or synapse number (Zhang et al., 2001; Gatto and Broadie, 2008). Both the pre and postsynaptic effects of the dFXR null are thought to be due to loss of translational suppression of regulators of the cytoskeleton including microtubule associated protein 1B (MAP1B), Rac1 and Profilin (Zhang et al., 2001; Lee et al., 2003; Reeve et al., 2005). This works strengthens a role for dFXR-mediated translational suppression in its neuronal function and highlights dFXR as a regulator of cytoskeletal components. In addition to regulation of synapse structure and number, dFXR regulates the number and type of postsynaptic glutamate receptor subunits at the NMJ. In the dFXR null fly, total glutamate receptor (GluR) levels at the NMJ are unchanged but the relative abundance of the A-class and B-class GluRs subtype are affected in opposing ways (GluRA accumulates and GluRB is lost) (Pan and Broadie, 2007).

Two recent papers characterized the synaptic locus, the developmental and experience-dependent role of dFXR in synaptic development in Drosophila (Gatto and Broadie, 2008; Tessier and Broadie, 2008). Constitutive presynaptic expression of dFXR rescued the excessive axon branching and excess presynaptic bouton number, but not increased synaptic function pointing to roles for both pre- and postsynaptic dFXR in development of the NMJ. Early induction of dFXR (during synaptogenesis) completely rescued the axon and bouton overgrowth (Gatto and Broadie, 2008). In contrast, acute induction of dFXR at the mature NMJ partially rescued increased bouton number, but not branching. These results indicate a role for dFXR in proper axon and bouton development, and a more limited role of dFXR in synapse maintenance (Gatto and Broadie, 2008). The axon pruning role of dFXR in the central nervous system, specifically, mushroom body neurons, as well as dFXR expression, depends on sensory experience (Tessier and Broadie, 2008). This work is the first to provide evidence for role for dFXR in experience and activity-dependent axon pruning. Visual experience drives expression of mammalian Fmr1 mRNA, suggesting that FMRP may play a similar role in the mammalian visual cortex (Gabel et al., 2004). In support of this idea, deficits in neocortical plasticity in response to sensory deprivation have been reported in the Fmr1 KO, discussed below (Dolen et al., 2007; Bureau et al., 2008).

Evidence for a presynaptic role of FMRP in formation and/or maintenance of local synaptic connectivity

More recent and functional characterization of the Fmr1 KO mice has revealed a role for FMRP in establishment and/or maintenance of synaptic connections, perhaps due to a presynaptic function of FMRP. Hanson and Madison (2007) devised a clever strategy to cross the Fmr1 KO mice with mice harboring GFP on the X chromosome (Hanson and Madison, 2007). The heterozygous female offspring had a “mosaic” co-expression of FMRP and GFP, in essence GFP should act as a reporter for FMRP expression and allowed the investigators to record from synaptically connected pairs of CA3 neurons in organotypic hippocampal slice cultures which varied with regard to their pre- or postsynaptic expression of FMRP. Surprisingly, they reported that the presynaptic loss of FMRP led to a reduction in the local, functional excitatory connections to CA3 neighbors (Hanson and Madison, 2007). In support of these findings, two studies of neocortical synaptic connectivity observed reduced synaptic connectivity in Fmr1 KO mice (Bureau et al., 2008; Gibson et al., 2008). Using dual whole cell patch recordings from synaptically coupled layer 4 neurons in the somatosensory cortex, a reduced number and strength of functional synaptic connections was observed from spiny stellate excitatory neurons onto both neighboring excitatory and fast-spiking inhibitory neurons in layer 4. Interestingly, the greatest deficit in excitatory drive was onto the inhibitory neurons (~ 50% decrease; Fig. 3) (Gibson et al., 2008). In contrast to the local excitatory connections, the strength of thalamically-evoked excitatory synapses onto L4 inhibitory neurons was normal. Because the excitatory connectivity deficit was common to targets of the L4 spiny stellate neurons, this suggests a role for presynaptic FMRP in L4 spiny stellate axons in the formation or maintenance of synaptic connections with their targets. In support of this idea, Bureau et al., (2008) used laser uncaging of glutamate to map neocortical connectivity and observed decreased connectivity of L4 neuron onto L2/3 pyramidal neurons in the somatosensory cortex. The decreased L4->L2/3 connectivity in Fmr1 KO resembles the connectivity in a sensory deprived cortex of a wildtpe mouse. Whisker deprivation fails to decrease functional connectivity of L4->L2/3 in the Fmr1 KO mice, perhaps because the Fmr1 KO cortex is already in a deprived state (Bureau et al., 2008). Interestingly, the L4->L2/3 connectivity deficit was developmentally restricted and was normal by 4 weeks of age. Whereas, the L4->L4 local connectivity deficit persisted for at least 4 weeks, suggesting it may be permanent (Gibson et al., 2008).

How to reconcile the findings of decreased connectivity with the structural “overgrowth” phenotype of the FXS mouse and fly? Bureau et al., observed that the axonal arbors from layer 4 neurons in the Fmr1 KO neurons were more diffuse and sparse. Specifically, the density of axonal projections was reduced in the center of the barrel and increased along the barrel borders. These diffuse axonal projections are consistent with a lack of proper axon pruning that may result in reduced appropriate synaptic connectivity at the center of the barrel (Fig. 3). A presynaptic role of FMRP in neocortical synaptic connectivity is suggested from these studies, and is supported by data demonstrating FMRP localization to growth cones and developing axons and FMRP interaction with a mRNAs for presynaptic proteins (Brown et al., 2001; Antar et al., 2006) (Fig. 1). In Fmr1 KO mice, growth cone filopodia of are more numerous, but are less dynamic and motile in comparison to wild-type mice which may lead to a reduction in synapse formation or maintenance (Antar et al., 2006). The work of Hanson and Madison (2007) and others suggests that FMRP has a presynaptic role in establishment and/or maintenance of local synaptic connectivity. Whereas, the observations of enhanced dendritic spine number in FXS models and loss of synapses with acute postsynaptic expression of FMRP highlight a postsynaptic role for FMRP in synapse elimination (Irwin et al., 2002; Pfeiffer and Huber, 2007). The diverse functions of FMRP in the nervous system is not surprising due to the number and diversity of its interacting mRNAs. Future experiments using acute and cell autonomous manipulation of FMRP in identified neuron populations is necessary to define and reconcile the current, but apparently disparate findings.

Hyperexcitable circuit function in Fragile X Syndrome

Although there are many synaptic phenotypes observed in FXS, the effects of these synaptic changes on overall circuit function is most relevant to understanding how alterations in brain function mediate behaviors observed with this disease. To fully understand circuit function in FXS, it is important to evaluate all components of the circuit, including inhibitory circuit function. Due to the co-morbidity of epilepsy with FXS, as well as the sensory hypersensitivity, it has been hypothesized that there is a circuit hyperexcitability (Miller et al., 1999; Musumeci et al., 1999; Musumeci et al., 2000; Hagerman, 2002).

Most relevant to the sensory hypersensitivity that occurs with FXS are studies examining circuitry in the sensory neocortex. As mentioned above, a large (~50%) deficit in local excitatory drive is observed onto fast spiking interneurons in L4 somatosensory cortex. In contrast, the reciprocal inhibitory postsynaptic currents (IPSCs) are normal (Fig. 3) (Gibson et al., 2008). Because of the profound decrease in excitatory drive onto local inhibitory neurons, it was predicted there would be a decrease in feedback inhibition in the neocortex. This deficit in feedback inhibition together with the findings of increased intrinsic membrane excitability of L4 excitatory spiny stellate neurons would be expected to lead to a hyperexcitable circuit. Consistent with this idea, stimulation of thalamocortical projections into L4, mimicking a sensory stimulus, lead to prolonged neocortical circuit activity, consistent with greater circuit excitability (Gibson et al., 2008). Although no decreases in local inhibitory synapse function were detected, Fmr1 KO mice are reported to have decreased parvalbumin-positive interneurons, typically fast-spiking, in nearly all layers of somatosensory cortex (Selby et al., 2007). However, decreases in parvalbumin immunoreactivity does not necessarily equate to fewer inhibitory neurons, but could be due to a reduction in parvalbumin protein levels in the neurons (Jiao et al., 2006). Additional evidence for decreased GABAergic function comes from studies demonstrating decreases in specific GABAa receptor subunits (either mRNA or protein; reviewed in (D’Hulst and Kooy, 2007). Overall, the decrease in excitatory drive onto inhibitory neurons, increased intrinsic excitability of excitatory neurons, and decreases in inhibitory neuron number and increased spine number on L5 neurons would be expected to result in a hyperexcitable circuit in sensory neocortex (Fig. 3). These changes may underlie the sensory hypersensitivity that is prevalent in Fragile X Syndrome. It will be important in future studies to determine if similar hyperexcitable circuit changes are prevalent to other neocortical layers and related brain regions such as the hippocampus. As discussed below, a group 1 metabotropic glutamate receptor triggered epilepsy is dramatically enhanced in hippocampal CA3 neurons of Fmr1 KO mice, indicating that hyperexcitability is prevalent in the Fragile X brain (Chuang et al., 2005).

Other studies have observed alterations in inhibitory neuron function in both the subiculum and the striatum. Consistent with a hyperexcitability of circuits in Fragile X, Curia et al., (2008) demonstrated a deficit in tonic GABAergic inhibition, but not synaptically released GABA (spontaneous IPSCs) onto subicular pyramidal neurons of Fmr1 KO mice (Curia et al., 2008). The loss of tonic inhibition suggests a decrease in extrasynaptic GABAa receptor function. Interestingly, there is evidence for increases in GABAergic miniature IPSCs onto medium spiny neurons in the striatum (Centonze et al., 2007). Because these striatal neurons are themselves GABAergic projection neurons, increased inhibitory drive onto these neurons would result in a disinhibition or hyperexcitability of the striatal output.

Changes in Synaptic Plasticity in FXS

The most common mental phenotype associated with FXS is a loss of cognitive ability. A prevailing view in neuroscience is that the phenomenon of synaptic plasticity – the ability of neurons to persistently strengthen (long-term potentiation, LTP) or weaken (long-term depression, LTD) individual synaptic connections in response to activity patterns – is a molecular mechanism underlying memory and cognition. Therefore, many studies have investigated whether the loss of FMRP results in impairments or alterations in synaptic plasticity. Two principle findings have emerged from this work: enhanced Gq-coupled receptor-dependent LTD and impaired cortical LTP in Fmr1 KO mice.

Gq-dependent LTD

Activation of Gq-coupled neurotransmitter receptors induces a long-term depression of synaptic transmission (LTD) in several regions of the brain (reviewed in (Massey and Bashir, 2007; Bellone et al., 2008)). The most well-characterized of these are the group 1 metabotropic glutamate receptors (mGluRs), mGluR1 and mGluR5, which mediate persistent changes in neurons and synaptic function and therefore are implicated in many forms of brain plasticity, including learning and memory, drug addiction, and chronic pain (reviewed in (Grueter et al., 2007; Dolen and Bear, 2008; Goudet et al., 2008). Most relevant to FXS, mGluR1 and 5 are canonically linked to translational activation in neurons and stimulate rapid synthesis of FMRP at synapses (Weiler and Greenough, 1993; Kacharmina et al., 2000; Banko et al., 2006; Park et al., 2008). Consequently, a common mechanism by which long-term synaptic plasticity is induced by group 1 mGluRs is through rapid and likely “local” protein synthesis (Merlin et al., 1998; Raymond et al., 2000; Huber et al., 2001; Karachot et al., 2001; Mameli et al., 2007; Waung et al., 2008). Notably, mGluR- induced LTD of CA1 hippocampal synapses requires rapid dendritic synthesis of pre-existing mRNAs (Huber et al., 2000).

Due to the link of mGluRs with FMRP, mGluR-dependent LTD was evaluated in the Fmr1 KO mice and was found to be enhanced in both the hippocampus and cerebellum (Huber et al., 2002; Koekkoek et al., 2005; Hou et al., 2006). Similarly, activation of the Gq coupled M1 muscarinic acetylcholine receptor (mAChR) induce protein synthesis dependent LTD which, like mGluR-LTD, is also enhanced in Fmr1 KO mice (Massey et al., 2001; Volk et al., 2007). These findings, combined with evidence for FMRP as a translational suppressor, suggested that FMRP acted to inhibit translation of proteins that were required for Gq-dependent LTD, termed “LTD proteins”. Because one of the proteins synthesized in response to mGluR activation is FMRP itself, it was suggested that FMRP may function as a negative feedback mechanism to limit mGluR-stimulated translation. In addition to mGluR-LTD, mGluR-induced epilepsy, measured as prolonged bursting of CA3 neurons also relies on protein synthesis and is dramatically enhanced in Fmr1 KO mice (Chuang et al., 2005). From these findings, it was suggested that FMRP may generally function to suppress mGluR and protein synthesis dependent plasticity, termed the “mGluR theory of Fragile X Syndrome” (Bear et al., 2004). Therefore, group 1 mGluR antagonism has been proposed as a therapy for FXS, for which there is remarkable experimental support (reviewed in (Dolen and Bear, 2008).

FMRP and Metabotropic Glutamate Receptors

What is known about the role of FMRP in mGluR-stimulated translation and plasticity? As mentioned above, to obtain localized protein expression RNA binding proteins like such as FMRP may serve two functions: 1) to suppress translation of mRNAs during transport and, 2) to function as a modifiable switch to allow or stimulate mRNA translation at the right time and place (Kindler et al., 2005; Wells, 2006). There is some evidence to support a role of FMRP in mGluR-stimulated protein synthesis in this capacity. MGluRs stimulate movement of FMRP and target mRNAs into dendrites where FMRP may function to facilitate transport and/or suppress translation of targets during transport (Antar et al., 2004; Dictenberg et al., 2008). However, at individual synapses or dendritic spines mGluRs stimulate FMRP translation, as well as a rapid ubiquitination and degradation of FMRP, which results in a net decrease in spine FMRP abundance (Weiler and Greenough, 1999; Antar et al., 2004; Hou et al., 2006) (Fig. 1). The purpose of the rapid and bidirectional regulation of FMRP by mGluRs is unclear. Possibly, the loss of synaptic FMRP may function to de-repress mRNA targets and allow translation. In addition to regulation of FMRP abundance, posttranslational modifications of FMRP, such as phosphorylation, or recruitment of FMRP from a translationally inactive mRNP or RNA granule to polysomes may “switch” its function from a suppressor to an activator of protein synthesis (Ceman et al., 2003; Wang et al., 2007). Consistent with this view, recent work demonstrates that mGluRs activate a protein phosphatase, PP2A, and rapid dephosphorylation of FMRP, which in turn stimulates translation of an FMRP target mRNA (Narayanan et al., 2007; Narayanan et al., 2008) (Fig. 1).

In support of a dual function of FMRP in translational control, there are enhanced protein synthesis rates and synaptic protein levels in Fmr1 KO mice and mGluR-stimulated translation is absent (Aschrafi et al., 2005; Qin et al., 2005a; Hou et al., 2006; Muddashetty et al., 2007; Zalfa et al., 2007; Liao et al., 2008). Recent work has also observed a deficit in protein synthesis in response to the Gq coupled M1 muscarinic acetylcholine receptors in Fmr1 KO mice, suggesting a more general role for FMRP in Gq coupled receptor-dependent translation (Volk et al., 2007). Although mGluR5 levels are normal in Fmr1 KO mice, there is evidence for a reduced association of mGluR5 with constitutive Homer isoforms, a synaptic scaffold and signaling protein (Giuffrida et al., 2005). Consequently, there is reduced localization of mGluR5, at the synapse or postsynaptic density. Importantly, mGluR5-Homer interactions are required for mGluRs to couple to activation of the translational machinery, specifically the PI3 kinase-mTOR (mammalian target of rapamycin) pathway (Ronesi and Huber, 2008b) (Fig. 1). Consistent with an uncoupling of mGluR5 from Homer, mGluRs fail to stimulate PI3K-mTOR in Fmr1 KO mice. In addition, recent work demonstrates that FMRP interacts with G-protein receptor kinase 2 (GRK2) protein and functions to maintain GRK2 in the cytoplasm (Wang et al., 2008). GRK2 phosphorylates mGluR1 and 5 and may contribute to altered mGluR function in FXS (reviewed in (Mao et al., 2008)). In the dFXR null fly, protein levels of the sole drosophila mGluR (DmGluRA) are elevated suggesting a direct regulation of mGluRs in this organism (Pan et al., 2008). In addition, the enhanced protein synthesis rates in the Fmr1 KO mouse may be at a ceiling such that ex vivo stimulation of mGluRs is ineffective (Todd et al., 2003; Hou et al., 2006; Westmark and Malter, 2007). Future experiments are required to establish the acute function of FMRP in activity-dependent translation as well as determine the effects of constitutive loss of FMRP on the neuronal translation, the latter of which is most relevant for understanding Fragile X Syndrome.

The lack of mGluR-stimulated protein synthesis in Fmr1 KO mice was difficult to reconcile with the enhanced mGluR-dependent LTD. Because Fmr1 KO mice have been reported to have elevated synaptic levels of some proteins known to be synthesized by mGluR activation, it was suggested loss of translational suppression by FMRP lead to an increase in the steady state levels of proteins necessary for mGluR-LTD (dubbed “LTD proteins”) (Zalfa et al., 2003; Hou et al., 2006; Westmark and Malter, 2007; Liao et al., 2008). A direct prediction from this hypothesis is that mGluR-LTD, which is normally blocked by acute administration of protein synthesis inhibitors, should be insensitive to blockade of translation in Fmr1 KO mice because the proteins necessary for mGluR-LTD expression are present or available at the synapse. In support of this hypothesis, mGluR- and M1 mAChR-induced LTD persists following acute application of protein synthesis inhibitors (Hou et al., 2006; Nosyreva and Huber, 2006; Volk et al., 2007).

Candidate plasticity proteins for LTD

To understand how FMRP regulates protein synthesis dependent synaptic plasticity it was necessary to determine the molecular mechanisms of mGluR-LTD, as well as the identity of the “LTD proteins”. mGluR-LTD is mediated by a rapid endocytosis and persistent decrease in surface expression of postsynaptic ionotropic AMPA receptors (Snyder et al., 2001; Moult et al., 2006; Zhang et al., 2008). During protein synthesis blockade, mGluRs trigger endocytosis of AMPARs, but AMPARs recycle back to the surface (Snyder et al., 2001; Waung et al., 2008). This result indicates that the newly synthesized “LTD proteins” function to maintain decreased surface AMPAR expression and are likely to regulate AMPAR endocytosis and are translationally suppressed by FMRP (Fig. 1). In support of this model, acute knockdown (KD) of FMRP in cultured rat hippocampal neurons with a small-interfering RNA results in an mGluR5-dependent removal of surface AMPA receptors (Nakamoto et al., 2007).

Recent studies have identified two candidate “LTD proteins” whose mRNAs interact with FMRP and encode proteins known to regulate AMPAR endocytosis. MAP1B is a well characterized dendritic, FMRP interacting mRNA, but its role in mGluR-triggered AMPAR endocytosis has only be recently elucidated (Darnell et al., 2001). MGluR treatment of hippocampal neurons increases MAP1B levels in dendrites, and constitutive knockdown of MAP1B prevents mGluR-induced AMPAR endocytosis (Hou et al., 2006; Davidkova and Carroll, 2007). MAP1b interacts with the GluR2 interacting protein and scaffold GRIP1 and DHPG increases this association (Seog, 2004; Davidkova and Carroll, 2007). Because GRIP1 stabilizes surface GluRs, the synthesis of MAP1b may serve to sequester GRIP1 away from the synapse and destabilize GluR surface expression.

Activity-dependent cytoskeletal associated protein (Arc/Arg3.1) is an abundant dendritic mRNA that interacts with FMRP (Lyford et al., 1995; Zalfa et al., 2003; Iacoangeli et al., 2008). Recent work demonstrated that Arc protein interacts with dynamin 2 and endophilin 3, components of the endocytosis machinery, and functions to increase AMPAR endocytosis rate, making Arc a good candidate for an “LTD protein” (Chowdhury et al., 2006; Rial Verde et al., 2006). Recently, we and Paul Worley’s group independently implicated Arc as an “LTD protein” in mGluR-LTD (Park et al., 2008; Waung et al., 2008). Group 1 mGluRs stimulate rapid synthesis of Arc in dendrites, mGluR-LTD is prevented in Arc KO mice, with Arc knockdown or acute blockade of new Arc synthesis using antisense oligonucleotides. The mechanism by which Arc maintains LTD is thought to be by a persistent (1 hour) increase in AMPAR endocytosis rate, which is caused by mGluR-LTD and require Arc mRNA translation. Crossing Fmr1 KO with Arc KO mice results in a reduced level of mGluR-LTD (Park et al., 2008). This data suggests that in the absence of FMRP, Arc protein is available to maintain LTD in the absence of new synthesis. Future experiments are required to determine if altered levels or translational control of Arc are responsible for the altered LTD phenotype in Fmr1 KO mice. If or how enhanced Gq dependent LTD leads to the cognitive symptoms of FXS is unknown. However, because Arc induction is highly linked to plasticity and memory formation (Plath et al., 2006; Tzingounis and Nicoll, 2006), alterations in Arc-dependent synaptic plasticity in Fragile X Syndrome may provide insight into the altered learning or plasticity-dependent behaviors in the disease.

Widespread Deficits in LTP in Fragile X Syndrome

Another likely contributor to the cognitive deficits in Fragile X Syndrome is the widespread deficit in LTP that is observed in Fmr1 KO mice. Multiple studies have reported a complete absence of LTP in the neocortex of Fmr1 KO mice, including visual, prefrontal and somatosensory cortices (Li et al., 2002; Zhao et al., 2005; Desai et al., 2006; Meredith et al., 2007; Wilson and Cox, 2007). Although initial studies demonstrated normal LTP in the hippocampus in Fmr1 KO mice (Godfraind et al., 1996; Paradee et al., 1999; Li et al., 2002; Larson et al., 2005), more recent work observes a decrease in the magnitude of LTP (Lauterborn et al., 2007; Hu et al., 2008)). Both in the hippocampus and neocortex the deficit in LTP can be overcome by increasing factors involved in LTP induction. For example, in the hippocampus, the lack of LTP is accompanied by a deficit in trafficking of GluR1 containing AMPA receptors and Ras-dependent activation of PI3 kinase, a pathway previously implicated in GluR1 insertion and LTP (Zhu et al., 2002; Qin et al., 2005b). The LTP deficit can be rescued by acute BDNF application or overexpression of upstream activators of PI3K (Lauterborn et al., 2007; Hu et al., 2008) suggesting that BDNF activation of PI3K may contribute its ability to rescue LTP. Interestingly, there appears to be a general deficit in PI3K activation in response to neurotransmitters, including histamine and group 1 mGluRs. This deficit has been suggested to arise from an uncoupling of Ras-to-PI3K or mGluR-Homer-PI3K Enhancer (PIKE) pathways (Hu et al., 2008; Ronesi and Huber, 2008b). Further investigation of the extent of altered PI3K regulation and localization in Fragile X Syndrome, as well as the link to FMRP, may help to determine the mechanisms of the synaptic plasticity phenotypes.

In neocortex, there is a deficit in LTP induced with a protocol that relies on the relative timing of EPSPs and postsynaptic action potentials (APs) or spikes, termed spike-timing dependent plasticity (STDP) (Desai et al., 2006; Meredith et al., 2007). A reduction of L-type Ca++ channels and a partial loss of Ca++ influx into the spines of layer 2/3 neurons in Fmr1 KO mice was observed (Meredith et al., 2007). Increasing the number of APs paired with EPSPs during LTP induction increased postsynaptic Ca2+ entry into Fmr1 KO spines and restored STD-LTP in Fmr1 KO mice. Importantly this work attributed the elongated spine structure to altered Ca2+ dynamics in the spine, therefore linking altered spine shape with a functional plasticity deficit. Overall, these studies conclude that LTP expression mechanism is intact in Fmr1 KO mice. Instead, there is a higher “threshold” for LTP induction that can be overcome by increasing factors during the induction of LTP, such as spine Ca2+ influx or activators of PI3K.

Due to the link of mGluRs with FMRP, the mGluR dependence of neocortical plasticity has been investigated in wildtype mice. The observed deficit in LTP in layer 5 neurons of visual cortex was due to a deficit in an mGluR5-dependent LTP (Wilson and Cox, 2007). Interestingly, spike timing dependent-LTD was analyzed in the neocortex of Fmr1 KO mice and was found to be normal. Although the neocortical LTD relied on mGluR5, it was independent of protein synthesis (Desai et al., 2006). This latter result is consistent with the known function of FMRP and indicates that FMRP regulation of mGluR-dependent LTD may be limited to the LTD paradigms that rely on protein synthesis.

Molecular mechanisms of FMRP-Dependent Synapse Alterations

Translational Control

What is known about the molecular mechanisms by which FMRP alters synapse number or structure? Based upon its canonical function in translational regulation, FMRP likely governs synaptic function through control of mRNA translation, perhaps locally at synapses or spines. In support of the idea that translational regulatory pathways impact dendritic structure and function, activation of the PI3K→Akt→mTOR pathway (or deletion of endogenous inhibitors), which stimulates cap-dependent translation, causes increased dendritic growth, branching and complexity and causes an increase in dendritic spine number or filopodia-like spines and a decrease in mushroom-shaped spines, a phenotype reminiscent of that seen in Fmr1 KO mice (Jaworski et al., 2005; Kumar et al., 2005; Tavazoie et al., 2005; Kwon et al., 2006). Conversely, a more direct inhibition of cap-dependent translation by overexpression of eIF4E binding protein, 4EBP, results in decreased dendritic complexity (Jaworski et al., 2005). Another RNA-binding protein, translocated-in-liposarcoma protein (TLS) are localized to dendrites and is trafficked at synapses in an mGluR-dependent manner (Fujii et al., 2005). TLS-KO mice display a reduction in mature spines and an increase in filopodia, similar to Fmr1-KO mice (Fujii et al., 2005). In addition, loss of the brain-specific, dendritic RNA-binding protein Staufen2 results in an overall decrease in spine and synapse number (Goetze et al., 2006).

Activity of group 1 mGluRs is also associated with changes in spine shape and number. Brief stimulation of group 1 mGluRs causes a translation-dependent increase in spine length (Vanderklish and Edelman, 2002). Genetic reduction of mGluR5 or acute treatment with mGluR antagonists reverses the alterations in dendritic spine number and length in Fmr1 KO neurons, suggesting that mGluR5 hyperfunction drives the structural spine changes (Dolen et al., 2007; de Vrij et al., 2008). Similarly, some, but not all of the pre- and postsynaptic effects of dFXR1 null fly are rescued by genetic or pharmacological antagonism of the drosophila mGluR, DmGluRA (McBride et al., 2005; Pan and Broadie, 2007; Pan et al., 2008). Thus, in the absence of FMRP, mGluR5-dependent transport and/or translation of critical mRNAs is likely abnormal, leading to an increase in spine length and filopodia number (Dictenberg et al., 2008). Many of the FMRP-interacting mRNAs encode for both pre- and postsynaptic proteins, making it likely that FMRP dependent translational control of a number of synaptic proteins contributes proper synapse development.

Regulation of the Cytoskeleton

FMRP also interacts with mRNAs or proteins that impact the cytoskeleton, a critical determinant of dendritic spine shape. Most evidence for FMRP regulation of the cytoskeleton comes from work in the fly. As mentioned above, dFXR interacts with mRNAs for Futsch (or MAP1b), dRac1, a small Rho GTPase, and Profilin, a regulator of actin dynamics, and suppresses their translation (Zhang et al., 2001; Lee et al., 2003; Reeve et al., 2005). Many of the neurite and synaptic phenotypes in the dFXR null fly are mimicked by overexpression these cytoskeletal regulators or are rescued by the reducing their expression supporting the idea that dFXR may translationally suppresses a program of functionally related proteins for proper neurite and synaptic development. In addition, dFXR and dRac1 interact with a common protein, CYFIP1 (also known as Sra-1; specifically Rac 1 associated protein) and these three genes show interactions in regulation of axon branching and synapse size in the Drosophila NMJ (Schenck et al., 2003). Interestingly, because CYFIP only interacts with the GTP-bound or active Rac1, it has been suggested that CYFIP availability may be determined in part by Rac1 activity and in turn regulate dFXR translational function. This mechanism also provides a link between control of the actin cytoskeleton and translation. As mentioned above, mammalian CYFIP1 interacts with FMRP and plays a role in suppression of translation initiation through interactions with eIF4E (Schenck et al., 2001; Napoli et al., 2008). In mammals, CYFIP also interacts with Rac, and Rac-dependent actin remodeling is enhanced in the absence of FMRP or with I304N mutated FMRP expression in mouse fibroblasts (Castets et al., 2005). The latter result suggests that FMRP-RNA interactions or translational control are important for the ability of FMRP to regulate the cytoskeleton. Finally, a downstream effector of Rac signaling, p21-activated kinase (PAK), is positively coupled with spine number, such that expression of a dominant-negative form of PAK (dnPAK) results in decreased spine density (Hayashi et al., 2004). Notably, introduction of dnPAK into Fmr1 KO mice led to a wildtype spine phenotype (Hayashi et al., 2007). Thus, the spine phenotype observed in Fmr1 KO mice bears a striking resemblance to that seen following increased Rac activity, suggesting that this pathway may be particularly important for FMRP regulation of the spine number and morphology through control of the actin cytoskeleton.

Concluding Remarks

Because FXS is caused by loss of function of a single gene, FMR1, it presents a valuable opportunity to uncover neurobiological underpinnings of mental retardation and autism. Furthermore, studies of the normal functions of FMR1 have revealed important roles for dendritic translation in synaptic plasticity and perhaps synapse development. Evidence supports the idea that the primary function of FMRP is to regulate RNA processing, (transport, translation and stability). FMRP binds to a number of dendritically localized mRNAs and/or mRNAs that encode synaptic proteins. Consequently, there are a number of synaptic phenotypes in FXS, as described herein. Future goals include a determination of the primary or acute, cell autonomous functions of FMRP, in contrast to the indirect or compensatory effects of constitutive FMRP loss. This will help to determine how the different synaptic phenotypes are related. For example, do the alterations in synapse development and number cause the synaptic plasticity deficits in Fmr1 KO mice? Or does FMRP play direct, but multiple roles in both synapse development and plasticity in adults? Despite the large number of FMRP mRNA targets that have been reported, little is known about how their expression and regulation is altered in FXS or if their dysregulation contributes to the FXS phenotype. Although FMRP interacts and likely regulates a number of mRNAs, many of the synapse structure and behavioral deficits are rescued by reduced mGluR5 function. Is the alterations in mGluR5 function caused by loss of the downstream translational suppression function of FMRP or are there more direct alterations in mGluR5 function in FXS? Resolution of these questions will lead to a better understanding of FMRP in normal brain function, how the loss of FMRP leads to mental retardation and autism, and development for better therapies for these prevalent diseases.

References

  1. Adinolfi S, Ramos A, Martin SR, Dal Piaz F, Pucci P, Bardoni B, Mandel JL, Pastore A. The N-terminus of the fragile X mental retardation protein contains a novel domain involved in dimerization and RNA binding. Biochemistry. 2003;42:10437–10444. doi: 10.1021/bi034909g. [DOI] [PubMed] [Google Scholar]
  2. Antar LN, Afroz R, Dictenberg JB, Carroll RC, Bassell GJ. Metabotropic glutamate receptor activation regulates fragile x mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses. J Neurosci. 2004;24:2648–2655. doi: 10.1523/JNEUROSCI.0099-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Antar LN, Dictenberg JB, Plociniak M, Afroz R, Bassell GJ. Localization of FMRP-associated mRNA granules and requirement of microtubules for activity-dependent trafficking in hippocampal neurons. Genes Brain Behav. 2005;4:350–359. doi: 10.1111/j.1601-183X.2005.00128.x. [DOI] [PubMed] [Google Scholar]
  4. Antar LN, Li C, Zhang H, Carroll RC, Bassell GJ. Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses. Mol Cell Neurosci. 2006 doi: 10.1016/j.mcn.2006.02.001. [DOI] [PubMed] [Google Scholar]
  5. Aschrafi A, Cunningham BA, Edelman GM, Vanderklish PW. The fragile X mental retardation protein and group I metabotropic glutamate receptors regulate levels of mRNA granules in brain. Proc Natl Acad Sci U S A. 2005;102:2180–2185. doi: 10.1073/pnas.0409803102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ashley CT, Jr, Wilkinson KD, Reines D, Warren ST. FMR1 protein: conserved RNP family domains and selective RNA binding. Science. 1993;262:563–566. doi: 10.1126/science.7692601. [DOI] [PubMed] [Google Scholar]
  7. Bagni C, Greenough WT. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat Rev Neurosci. 2005;6:376–387. doi: 10.1038/nrn1667. [DOI] [PubMed] [Google Scholar]
  8. Bakker CE, de Diego Otero Y, Bontekoe C, Raghoe P, Luteijn T, Hoogeveen AT, Oostra BA, Willemsen R. Immunocytochemical and biochemical characterization of FMRP, FXR1P, and FXR2P in the mouse. Exp Cell Res. 2000;258:162–170. doi: 10.1006/excr.2000.4932. [DOI] [PubMed] [Google Scholar]
  9. Bakker DB. Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium. Cell. 1994;78:23–33. [PubMed] [Google Scholar]
  10. Banko JL, Hou L, Poulin F, Sonenberg N, Klann E. Regulation of eukaryotic initiation factor 4E by converging signaling pathways during metabotropic glutamate receptor-dependent long-term depression. J Neurosci. 2006;26:2167–2173. doi: 10.1523/JNEUROSCI.5196-05.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bassell GJ, Warren ST. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron. 2008;60:201–214. doi: 10.1016/j.neuron.2008.10.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Bear MF. Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes Brain Behav. 2005;4:393–398. doi: 10.1111/j.1601-183X.2005.00135.x. [DOI] [PubMed] [Google Scholar]
  13. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27:370–377. doi: 10.1016/j.tins.2004.04.009. [DOI] [PubMed] [Google Scholar]
  14. Bellone C, Luscher C, Mameli M. Mechanisms of synaptic depression triggered by metabotropic glutamate receptors. Cell Mol Life Sci. 2008;65:2913–2923. doi: 10.1007/s00018-008-8263-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Brennan FX, Albeck DS, Paylor R. Fmr1 knockout mice are impaired in a leverpress escape/avoidance task. Genes Brain Behav. 2006;5:467–471. doi: 10.1111/j.1601-183X.2005.00183.x. [DOI] [PubMed] [Google Scholar]
  16. Brown V, Jin P, Ceman S, Darnell JC, O’Donnell WT, Tenenbaum SA, Jin X, Feng Y, Wilkinson KD, Keene JD, Darnell RB, Warren ST. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell. 2001;107:477–487. doi: 10.1016/s0092-8674(01)00568-2. [DOI] [PubMed] [Google Scholar]
  17. Bureau I, Shepherd GM, Svoboda K. Circuit and plasticity defects in the developing somatosensory cortex of FMR1 knock-out mice. J Neurosci. 2008;28:5178–5188. doi: 10.1523/JNEUROSCI.1076-08.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Castets M, Schaeffer C, Bechara E, Schenck A, Khandjian EW, Luche S, Moine H, Rabilloud T, Mandel JL, Bardoni B. FMRP interferes with the Rac1 pathway and controls actin cytoskeleton dynamics in murine fibroblasts. Hum Mol Genet. 2005;14:835–844. doi: 10.1093/hmg/ddi077. [DOI] [PubMed] [Google Scholar]
  19. Caudy AA, Myers M, Hannon GJ, Hammond SM. Fragile X-related protein and VIG associate with the RNA interference machinery. Genes Dev. 2002;16:2491–2496. doi: 10.1101/gad.1025202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ceman S, O’Donnell WT, Reed M, Patton S, Pohl J, Warren ST. Phosphorylation influences the translation state of FMRP-associated polyribosomes. Hum Mol Genet. 2003;12:3295–3305. doi: 10.1093/hmg/ddg350. [DOI] [PubMed] [Google Scholar]
  21. Centonze D, Rossi S, Mercaldo V, Napoli I, Ciotti MT, Chiara VD, Musella A, Prosperetti C, Calabresi P, Bernardi G, Bagni C. Abnormal Striatal GABA Transmission in the Mouse Model for the Fragile X Syndrome. Biol Psychiatry. 2007 doi: 10.1016/j.biopsych.2007.09.008. [DOI] [PubMed] [Google Scholar]
  22. Chowdhury S, Shepherd JD, Okuno H, Lyford G, Petralia RS, Plath N, Kuhl D, Huganir RL, Worley PF. Arc/Arg3.1 interacts with the endocytic machinery to regulate AMPA receptor trafficking. Neuron. 2006;52:445–459. doi: 10.1016/j.neuron.2006.08.033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Chuang SC, Zhao W, Bauchwitz R, Yan Q, Bianchi R, Wong RK. Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. J Neurosci. 2005;25:8048–8055. doi: 10.1523/JNEUROSCI.1777-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Curia G, Papouin T, Seguela P, Avoli M. Downregulation of Tonic GABAergic Inhibition in a Mouse Model of Fragile X Syndrome. Cereb Cortex. 2008 doi: 10.1093/cercor/bhn159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. D’Hulst C, Kooy RF. The GABAA receptor: a novel target for treatment of fragile X? Trends Neurosci. 2007;30:425–431. doi: 10.1016/j.tins.2007.06.003. [DOI] [PubMed] [Google Scholar]
  26. Darnell JC, Mostovetsky O, Darnell RB. FMRP RNA targets: identification and validation. Genes Brain Behav. 2005a;4:341–349. doi: 10.1111/j.1601-183X.2005.00144.x. [DOI] [PubMed] [Google Scholar]
  27. Darnell JC, Jensen KB, Jin P, Brown V, Warren ST, Darnell RB. Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell. 2001;107:489–499. doi: 10.1016/s0092-8674(01)00566-9. [DOI] [PubMed] [Google Scholar]
  28. Darnell JC, Fraser CE, Mostovetsky O, Stefani G, Jones TA, Eddy SR, Darnell RB. Kissing complex RNAs mediate interaction between the Fragile-X mental retardation protein KH2 domain and brain polyribosomes. Genes Dev. 2005b;19:903–918. doi: 10.1101/gad.1276805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Davidkova G, Carroll RC. Characterization of the role of microtubule-associated protein 1B in metabotropic glutamate receptor-mediated endocytosis of AMPA receptors in hippocampus. J Neurosci. 2007;27:13273–13278. doi: 10.1523/JNEUROSCI.3334-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Davidovic L, Jaglin XH, Lepagnol-Bestel AM, Tremblay S, Simonneau M, Bardoni B, Khandjian EW. The fragile X mental retardation protein is a molecular adaptor between the neurospecific KIF3C kinesin and dendritic RNA granules. Hum Mol Genet. 2007;16:3047–3058. doi: 10.1093/hmg/ddm263. [DOI] [PubMed] [Google Scholar]
  31. De Boulle K, Verkerk AJ, Reyniers E, Vits L, Hendrickx J, Van Roy B, Van den Bos F, de Graaff E, Oostra BA, Willems PJ. A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nat Genet. 1993;3:31–35. doi: 10.1038/ng0193-31. [DOI] [PubMed] [Google Scholar]
  32. De Diego Otero Y, Severijnen LA, van Cappellen G, Schrier M, Oostra B, Willemsen R. Transport of fragile X mental retardation protein via granules in neurites of PC12 cells. Mol Cell Biol. 2002;22:8332–8341. doi: 10.1128/MCB.22.23.8332-8341.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. de Vrij FM, Levenga J, van der Linde HC, Koekkoek SK, De Zeeuw CI, Nelson DL, Oostra BA, Willemsen R. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis. 2008;31:127–132. doi: 10.1016/j.nbd.2008.04.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Desai NS, Casimiro TM, Gruber SM, Vanderklish PW. Early postnatal plasticity in neocortex of Fmr1 knockout mice. J Neurophysiol. 2006;96:1734–1745. doi: 10.1152/jn.00221.2006. [DOI] [PubMed] [Google Scholar]
  35. Dictenberg JB, Swanger SA, Antar LN, Singer RH, Bassell GJ. A direct role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine morphogenesis to fragile X syndrome. Dev Cell. 2008;14:926–939. doi: 10.1016/j.devcel.2008.04.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Dolen G, Bear MF. Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J Physiol. 2008;586:1503–1508. doi: 10.1113/jphysiol.2008.150722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, Bear MF. Correction of Fragile X Syndrome in Mice. Neuron. 2007;56:955–962. doi: 10.1016/j.neuron.2007.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Dolzhanskaya N, Sung YJ, Conti J, Currie JR, Denman RB. The fragile X mental retardation protein interacts with U-rich RNAs in a yeast three-hybrid system. Biochem Biophys Res Commun. 2003;305:434–441. doi: 10.1016/s0006-291x(03)00766-6. [DOI] [PubMed] [Google Scholar]
  39. Eberhart DE, Malter HE, Feng Y, Warren ST. The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum Mol Genet. 1996;5:1083–1091. doi: 10.1093/hmg/5.8.1083. [DOI] [PubMed] [Google Scholar]
  40. Estes PS, O’Shea M, Clasen S, Zarnescu DC. Fragile X protein controls the efficacy of mRNA transport in Drosophila neurons. Mol Cell Neurosci. 2008;39:170–179. doi: 10.1016/j.mcn.2008.06.012. [DOI] [PubMed] [Google Scholar]
  41. Feng Y. Fragile X mental retardation: misregulation of protein synthesis in the developing brain? Microsc Res Tech. 2002;57:145–147. doi: 10.1002/jemt.10063. [DOI] [PubMed] [Google Scholar]
  42. Feng Y, Gutekunst CA, Eberhart DE, Yi H, Warren ST, Hersch SM. Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes. J Neurosci. 1997a;17:1539–1547. doi: 10.1523/JNEUROSCI.17-05-01539.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Feng Y, Absher D, Eberhart DE, Brown V, Malter HE, Warren ST. FMRP associates with polyribosomes as an mRNP, and the I304N mutation of severe fragile X syndrome abolishes this association. Mol Cell. 1997b;1:109–118. doi: 10.1016/s1097-2765(00)80012-x. [DOI] [PubMed] [Google Scholar]
  44. Fiala JC, Feinberg M, Popov V, Harris KM. Synaptogenesis via dendritic filopodia in developing hippocampal area CA1. J Neurosci. 1998;18:8900–8911. doi: 10.1523/JNEUROSCI.18-21-08900.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Fujii R, Okabe S, Urushido T, Inoue K, Yoshimura A, Tachibana T, Nishikawa T, Hicks GG, Takumi T. The RNA binding protein TLS is translocated to dendritic spines by mGluR5 activation and regulates spine morphology. Curr Biol. 2005;15:587–593. doi: 10.1016/j.cub.2005.01.058. [DOI] [PubMed] [Google Scholar]
  46. Gabel LA, Won S, Kawai H, McKinney M, Tartakoff AM, Fallon JR. Visual experience regulates transient expression and dendritic localization of fragile X mental retardation protein. J Neurosci. 2004;24:10579–10583. doi: 10.1523/JNEUROSCI.2185-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Galvez R, Greenough WT. Sequence of abnormal dendritic spine development in primary somatosensory cortex of a mouse model of the fragile X mental retardation syndrome. Am J Med Genet A. 2005;135:155–160. doi: 10.1002/ajmg.a.30709. [DOI] [PubMed] [Google Scholar]
  48. Galvez R, Gopal AR, Greenough WT. Somatosensory cortical barrel dendritic abnormalities in a mouse model of the fragile X mental retardation syndrome. Brain Res. 2003;971:83–89. doi: 10.1016/s0006-8993(03)02363-1. [DOI] [PubMed] [Google Scholar]
  49. Gao FB. Understanding fragile X syndrome: insights from retarded flies. Neuron. 2002;34:859–862. doi: 10.1016/s0896-6273(02)00740-7. [DOI] [PubMed] [Google Scholar]
  50. Garber K, Smith KT, Reines D, Warren ST. Transcription, translation and fragile X syndrome. Curr Opin Genet Dev. 2006;16:270–275. doi: 10.1016/j.gde.2006.04.010. [DOI] [PubMed] [Google Scholar]
  51. Gatto CL, Broadie K. Temporal requirements of the fragile X mental retardation protein in the regulation of synaptic structure. Development. 2008;135:2637–2648. doi: 10.1242/dev.022244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Gibson JR, Bartley AF, Hays SA, Huber KM. Imbalance of Neocortical Excitation and Inhibition and Altered UP States Reflect Network Hyperexcitability in the Mouse Model of Fragile X Syndrome. J Neurophysiol. 2008;100:2615–2626. doi: 10.1152/jn.90752.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Gibson TJ, Rice PM, Thompson JD, Heringa J. KH domains within the FMR1 sequence suggest that fragile X syndrome stems from a defect in RNA metabolism. Trends Biochem Sci. 1993;18:331–333. doi: 10.1016/0968-0004(93)90068-x. [DOI] [PubMed] [Google Scholar]
  54. Giuffrida R, Musumeci S, D’Antoni S, Bonaccorso CM, Giuffrida-Stella AM, Oostra BA, Catania MV. A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive homer proteins in a mouse model of fragile X syndrome. J Neurosci. 2005;25:8908–8916. doi: 10.1523/JNEUROSCI.0932-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Godfraind JM, Reyniers E, De Boulle K, R DH, De Deyn PP, Bakker CE, Oostra BA, Kooy RF, Willems PJ. Long-term potentiation in the hippocampus of fragile X knockout mice. Am J Med Genet. 1996;64:246–251. doi: 10.1002/(SICI)1096-8628(19960809)64:2<246::AID-AJMG2>3.0.CO;2-S. [DOI] [PubMed] [Google Scholar]
  56. Goetze B, Tuebing F, Xie Y, Dorostkar MM, Thomas S, Pehl U, Boehm S, Macchi P, Kiebler MA. The brain-specific double-stranded RNA-binding protein Staufen2 is required for dendritic spine morphogenesis. J Cell Biol. 2006;172:221–231. doi: 10.1083/jcb.200509035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Goudet C, Magnaghi V, Landry M, Nagy F, Gereau RWt, Pin JP. Metabotropic receptors for glutamate and GABA in pain. Brain Res Rev. 2008 doi: 10.1016/j.brainresrev.2008.12.007. [DOI] [PubMed] [Google Scholar]
  58. Grossman AW, Elisseou NM, McKinney BC, Greenough WT. Hippocampal pyramidal cells in adult Fmr1 knockout mice exhibit an immature-appearing profile of dendritic spines. Brain Res. 2006;1084:158–164. doi: 10.1016/j.brainres.2006.02.044. [DOI] [PubMed] [Google Scholar]
  59. Grueter BA, McElligott ZA, Winder DG. Group I mGluRs and long-term depression: potential roles in addiction? Mol Neurobiol. 2007;36:232–244. doi: 10.1007/s12035-007-0037-7. [DOI] [PubMed] [Google Scholar]
  60. Grutzendler J, Kasthuri N, Gan WB. Long-term dendritic spine stability in the adult cortex. Nature. 2002;420:812–816. doi: 10.1038/nature01276. [DOI] [PubMed] [Google Scholar]
  61. Hagerman R. The physical and behavioral phenotype. In: Hagerman R, Hagerman P, editors. Fragile X Syndrome: Diagnosis, Treatment, and Research. Baltimore: The Johns Hopkins University Press; 2002. pp. 3–109. [Google Scholar]
  62. Hagerman RJ, Ono MY, Hagerman PJ. Recent advances in fragile X: a model for autism and neurodegeneration. Curr Opin Psychiatry. 2005;18:490–496. doi: 10.1097/01.yco.0000179485.39520.b0. [DOI] [PubMed] [Google Scholar]
  63. Hanson JE, Madison DV. Presynaptic FMR1 genotype influences the degree of synaptic connectivity in a mosaic mouse model of fragile X syndrome. J Neurosci. 2007;27:4014–4018. doi: 10.1523/JNEUROSCI.4717-06.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Hayashi ML, Rao BS, Seo JS, Choi HS, Dolan BM, Choi SY, Chattarji S, Tonegawa S. Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. Proc Natl Acad Sci U S A. 2007;104:11489–11494. doi: 10.1073/pnas.0705003104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Hayashi ML, Choi SY, Rao BS, Jung HY, Lee HK, Zhang D, Chattarji S, Kirkwood A, Tonegawa S. Altered cortical synaptic morphology and impaired memory consolidation in forebrain-specific dominant-negative PAK transgenic mice. Neuron. 2004;42:773–787. doi: 10.1016/j.neuron.2004.05.003. [DOI] [PubMed] [Google Scholar]
  66. Hinton VJ, Brown WT, Wisniewski K, Rudelli RD. Analysis of neocortex in three males with the fragile X syndrome. Am J Med Genet. 1991;41:289–294. doi: 10.1002/ajmg.1320410306. [DOI] [PubMed] [Google Scholar]
  67. Honeycutt A, Dunlap L, Chen H, al Homsi G. MMWR Morb Mortal Wkly Rep, 2004/01/30. Centers for Disease Control and Prevention; 2004. Economic costs associated with mental retardation, cerebral palsy, hearing loss, and vision impairment--United States, 2003; pp. 57–59. [PubMed] [Google Scholar]
  68. Hoogeveen AT, Willemsen R, Oostra BA. Fragile X syndrome, the Fragile X related proteins, and animal models. Microsc Res Tech. 2002;57:148–155. doi: 10.1002/jemt.10064. [DOI] [PubMed] [Google Scholar]
  69. Hou L, Antion MD, Hu D, Spencer CM, Paylor R, Klann E. Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron. 2006;51:441–454. doi: 10.1016/j.neuron.2006.07.005. [DOI] [PubMed] [Google Scholar]
  70. Hu H, Qin Y, Bochorishvili G, Zhu Y, van Aelst L, Zhu JJ. Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome. J Neurosci. 2008;28:7847–7862. doi: 10.1523/JNEUROSCI.1496-08.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Huber KM, Kayser MS, Bear MF. Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent LTD. Science. 2000;288:1254–1257. doi: 10.1126/science.288.5469.1254. [DOI] [PubMed] [Google Scholar]
  72. Huber KM, Roder JC, Bear MF. Chemical induction of mGluR5- and protein synthesis--dependent long-term depression in hippocampal area CA1. J Neurophysiol. 2001;86:321–325. doi: 10.1152/jn.2001.86.1.321. [DOI] [PubMed] [Google Scholar]
  73. Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile-X mental retardation. Proc Natl Acad Sci. 2002;99:7746–7750. doi: 10.1073/pnas.122205699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Iacoangeli A, Rozhdestvensky TS, Dolzhanskaya N, Tournier B, Schutt J, Brosius J, Denman RB, Khandjian EW, Kindler S, Tiedge H. On BC1 RNA and the fragile X mental retardation protein. Proc Natl Acad Sci U S A. 2008;105:734–739. doi: 10.1073/pnas.0710991105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Irwin SA, Patel B, Idupulapati M, Harris JB, Crisostomo RA, Larsen BP, Kooy F, Willems PJ, Cras P, Kozlowski PB, Swain RA, Weiler IJ, Greenough WT. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am J Med Genet. 2001;98:161–167. doi: 10.1002/1096-8628(20010115)98:2<161::aid-ajmg1025>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  76. Irwin SA, Idupulapati M, Gilbert ME, Harris JB, Chakravarti AB, Rogers EJ, Crisostomo RA, Larsen BP, Mehta A, Alcantara CJ, Patel B, Swain RA, Weiler IJ, Oostra BA, Greenough WT. Dendritic spine and dendritic field characteristics of layer V pyramidal neurons in the visual cortex of fragile-X knockout mice. Am J Med Genet. 2002;111:140–146. doi: 10.1002/ajmg.10500. [DOI] [PubMed] [Google Scholar]
  77. Jaworski J, Spangler S, Seeburg DP, Hoogenraad CC, Sheng M. Control of dendritic arborization by the phosphoinositide-3′-kinase-Akt-mammalian target of rapamycin pathway. J Neurosci. 2005;25:11300–11312. doi: 10.1523/JNEUROSCI.2270-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Jiao Y, Zhang C, Yanagawa Y, Sun QQ. Major effects of sensory experiences on the neocortical inhibitory circuits. J Neurosci. 2006;26:8691–8701. doi: 10.1523/JNEUROSCI.2478-06.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Jin P, Zarnescu DC, Ceman S, Nakamoto M, Mowrey J, Jongens TA, Nelson DL, Moses K, Warren ST. Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat Neurosci. 2004;7:113–117. doi: 10.1038/nn1174. [DOI] [PubMed] [Google Scholar]
  80. Kacharmina JE, Job C, Crino P, Eberwine J. Stimulation of glutamate receptor protein synthesis and membrane insertion within isolated neuronal dendrites. Proc Natl Acad Sci U S A. 2000;97:11545–11550. doi: 10.1073/pnas.97.21.11545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Kanai Y, Dohmae N, Hirokawa N. Kinesin transports RNA: isolation and characterization of an RNA-transporting granule. Neuron. 2004;43:513–525. doi: 10.1016/j.neuron.2004.07.022. [DOI] [PubMed] [Google Scholar]
  82. Karachot L, Shirai Y, Vigot R, Yamamori T, Ito M. Induction of long-term depression in cerebellar Purkinje cells requires a rapidly turned over protein. J Neurophysiol. 2001;86:280–289. doi: 10.1152/jn.2001.86.1.280. [DOI] [PubMed] [Google Scholar]
  83. Kau AS, Tierney E, Bukelis I, Stump MH, Kates WR, Trescher WH, Kaufmann WE. Social behavior profile in young males with fragile X syndrome: characteristics and specificity. Am J Med Genet A. 2004;126:9–17. doi: 10.1002/ajmg.a.20218. [DOI] [PubMed] [Google Scholar]
  84. Kaufmann WE, Moser HW. Dendritic anomalies in disorders associated with mental retardation. Cereb Cortex. 2000;10:981–991. doi: 10.1093/cercor/10.10.981. [DOI] [PubMed] [Google Scholar]
  85. Kaufmann WE, Cortell R, Kau AS, Bukelis I, Tierney E, Gray RM, Cox C, Capone GT, Stanard P. Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. Am J Med Genet A. 2004;129:225–234. doi: 10.1002/ajmg.a.30229. [DOI] [PubMed] [Google Scholar]
  86. Khandjian EW, Corbin F, Woerly S, Rousseau F. The fragile X mental retardation protein is associated with ribosomes. Nat Genet. 1996;12:91–93. doi: 10.1038/ng0196-91. [DOI] [PubMed] [Google Scholar]
  87. Khandjian EW, Huot ME, Tremblay S, Davidovic L, Mazroui R, Bardoni B. Biochemical evidence for the association of fragile X mental retardation protein with brain polyribosomal ribonucleoparticles. Proc Natl Acad Sci U S A. 2004;101:13357–13362. doi: 10.1073/pnas.0405398101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Kindler S, Wang H, Richter D, Tiedge H. RNA transport and local control of translation. Annu Rev Cell Dev Biol. 2005;21:223–245. doi: 10.1146/annurev.cellbio.21.122303.120653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Koekkoek SK, Yamaguchi K, Milojkovic BA, Dortland BR, Ruigrok TJ, Maex R, De Graaf W, Smit AE, VanderWerf F, Bakker CE, Willemsen R, Ikeda T, Kakizawa S, Onodera K, Nelson DL, Mientjes E, Joosten M, De Schutter E, Oostra BA, Ito M, De Zeeuw CI. Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome. Neuron. 2005;47:339–352. doi: 10.1016/j.neuron.2005.07.005. [DOI] [PubMed] [Google Scholar]
  90. Kopec CD, Li B, Wei W, Boehm J, Malinow R. Glutamate receptor exocytosis and spine enlargement during chemically induced long-term potentiation. J Neurosci. 2006;26:2000–2009. doi: 10.1523/JNEUROSCI.3918-05.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Kumar V, Zhang MX, Swank MW, Kunz J, Wu GY. Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J Neurosci. 2005;25:11288–11299. doi: 10.1523/JNEUROSCI.2284-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Kwon CH, Luikart BW, Powell CM, Zhou J, Matheny SA, Zhang W, Li Y, Baker SJ, Parada LF. Pten regulates neuronal arborization and social interaction in mice. Neuron. 2006;50:377–388. doi: 10.1016/j.neuron.2006.03.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Laggerbauer B, Ostareck D, Keidel E, Ostareck-Lederer A, Fischer U. Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum Mol Genet. 2001;10:329–338. doi: 10.1093/hmg/10.4.329. [DOI] [PubMed] [Google Scholar]
  94. Larson J, Jessen RE, Kim D, Fine AK, du Hoffmann J. Age-dependent and selective impairment of long-term potentiation in the anterior piriform cortex of mice lacking the fragile X mental retardation protein. J Neurosci. 2005;25:9460–9469. doi: 10.1523/JNEUROSCI.2638-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Larson SA, Lakin KC, Anderson L, Kwak N, Lee JH, Anderson D. Prevalence of mental retardation and developmental disabilities: estimates from the 1994/1995 National Health Interview Survey Disability Supplements. Am J Ment Retard. 2001;106:231–252. [PubMed] [Google Scholar]
  96. Lauterborn JC, Rex CS, Kramar E, Chen LY, Pandyarajan V, Lynch G, Gall CM. Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. J Neurosci. 2007;27:10685–10694. doi: 10.1523/JNEUROSCI.2624-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Lee A, Li W, Xu K, Bogert BA, Su K, Gao FB. Control of dendritic development by the Drosophila fragile X-related gene involves the small GTPase Rac1. Development. 2003;130:5543–5552. doi: 10.1242/dev.00792. [DOI] [PubMed] [Google Scholar]
  98. Li J, Pelletier MR, Perez Velazquez JL, Carlen PL. Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. Mol Cell Neurosci. 2002;19:138–151. doi: 10.1006/mcne.2001.1085. [DOI] [PubMed] [Google Scholar]
  99. Li Z, Zhang Y, Ku L, Wilkinson KD, Warren ST, Feng Y. The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res. 2001;29:2276–2283. doi: 10.1093/nar/29.11.2276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Liao L, Park SK, Xu T, Vanderklish P, Yates JR., 3rd Quantitative proteomic analysis of primary neurons reveals diverse changes in synaptic protein content in fmr1 knockout mice. Proc Natl Acad Sci U S A. 2008;105:15281–15286. doi: 10.1073/pnas.0804678105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev. 2004;10:31–41. doi: 10.1002/mrdd.20006. [DOI] [PubMed] [Google Scholar]
  102. Loesch DZ, Huggins RM, Bui QM, Epstein JL, Taylor AK, Hagerman RJ. Effect of the deficits of fragile X mental retardation protein on cognitive status of fragile x males and females assessed by robust pedigree analysis. J Dev Behav Pediatr. 2002;23:416–423. doi: 10.1097/00004703-200212000-00004. [DOI] [PubMed] [Google Scholar]
  103. Loesch DZ, Bui QM, Grigsby J, Butler E, Epstein J, Huggins RM, Taylor AK, Hagerman RJ. Effect of the fragile X status categories and the fragile X mental retardation protein levels on executive functioning in males and females with fragile X. Neuropsychology. 2003;17:646–657. doi: 10.1037/0894-4105.17.4.646. [DOI] [PubMed] [Google Scholar]
  104. Lu R, Wang H, Liang Z, Ku L, O’Donnell WT, Li W, Warren ST, Feng Y. The fragile X protein controls microtubule-associated protein 1B translation and microtubule stability in brain neuron development. Proc Natl Acad Sci U S A. 2004;101:15201–15206. doi: 10.1073/pnas.0404995101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Lugenbeel KA, Peier AM, Carson NL, Chudley AE, Nelson DL. Intragenic loss of function mutations demonstrate the primary role of FMR1 in fragile X syndrome. Nat Genet. 1995;10:483–485. doi: 10.1038/ng0895-483. [DOI] [PubMed] [Google Scholar]
  106. Lyford GL, Yamagata K, Kaufmann WE, Barnes CA, Sanders LK, Copeland NG, Gilbert DJ, Jenkins NA, Lanahan AA, Worley PF. Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites. Neuron. 1995;14:433–445. doi: 10.1016/0896-6273(95)90299-6. [DOI] [PubMed] [Google Scholar]
  107. Mameli M, Balland B, Lujan R, Luscher C. Rapid synthesis and synaptic insertion of GluR2 for mGluR-LTD in the ventral tegmental area. Science. 2007;317:530–533. doi: 10.1126/science.1142365. [DOI] [PubMed] [Google Scholar]
  108. Mao LM, Liu XY, Zhang GC, Chu XP, Fibuch EE, Wang LS, Liu Z, Wang JQ. Phosphorylation of group I metabotropic glutamate receptors (mGluR1/5) in vitro and in vivo. Neuropharmacology. 2008;55:403–408. doi: 10.1016/j.neuropharm.2008.05.034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Marin-Padilla M. Structural abnormalities of the cerebral cortex in human chromosomal aberrations: a Golgi study. Brain Res. 1972;44:625–629. doi: 10.1016/0006-8993(72)90324-1. [DOI] [PubMed] [Google Scholar]
  110. Markus EJ, Petit TL. Neocortical synaptogenesis, aging, and behavior: lifespan development in the motor-sensory system of the rat. Exp Neurol. 1987;96:262–278. doi: 10.1016/0014-4886(87)90045-8. [DOI] [PubMed] [Google Scholar]
  111. Massey PV, Bashir ZI. Long-term depression: multiple forms and implications for brain function. Trends Neurosci. 2007;30:176–184. doi: 10.1016/j.tins.2007.02.005. [DOI] [PubMed] [Google Scholar]
  112. Massey PV, Bhabra G, Cho K, Brown MW, Bashir ZI. Activation of muscarinic receptors induces protein synthesis-dependent long-lasting depression in the perirhinal cortex. Eur J Neurosci. 2001;14:145–152. doi: 10.1046/j.0953-816x.2001.01631.x. [DOI] [PubMed] [Google Scholar]
  113. Matsuzaki M, Ellis-Davies GC, Nemoto T, Miyashita Y, Iino M, Kasai H. Dendritic spine geometry is critical for AMPA receptor expression in hippocampal CA1 pyramidal neurons. Nat Neurosci. 2001;4:1086–1092. doi: 10.1038/nn736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. McBride SM, Choi CH, Wang Y, Liebelt D, Braunstein E, Ferreiro D, Sehgal A, Siwicki KK, Dockendorff TC, Nguyen HT, McDonald TV, Jongens TA. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron. 2005;45:753–764. doi: 10.1016/j.neuron.2005.01.038. [DOI] [PubMed] [Google Scholar]
  115. McKinney BC, Grossman AW, Elisseou NM, Greenough WT. Dendritic spine abnormalities in the occipital cortex of C57BL/6 Fmr1 knockout mice. Am J Med Genet B Neuropsychiatr Genet. 2005;136:98–102. doi: 10.1002/ajmg.b.30183. [DOI] [PubMed] [Google Scholar]
  116. Meredith RM, Holmgren CD, Weidum M, Burnashev N, Mansvelder HD. Increased threshold for spike-timing-dependent plasticity is caused by unreliable calcium signaling in mice lacking fragile X gene FMR1. Neuron. 2007;54:627–638. doi: 10.1016/j.neuron.2007.04.028. [DOI] [PubMed] [Google Scholar]
  117. Merlin LR, Bergold PJ, Wong RK. Requirement of protein synthesis for group I mGluR-mediated induction of epileptiform discharges. J Neurophysiol. 1998;80:989–993. doi: 10.1152/jn.1998.80.2.989. [DOI] [PubMed] [Google Scholar]
  118. Miller LJ, McIntosh DN, McGrath J, Shyu V, Lampe M, Taylor AK, Tassone F, Neitzel K, Stackhouse T, Hagerman RJ. Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report. Am J Med Genet. 1999;83:268–279. [PubMed] [Google Scholar]
  119. Miyashiro KY, Beckel-Mitchener A, Purk TP, Becker KG, Barret T, Liu L, Carbonetto S, Weiler IJ, Greenough WT, Eberwine J. RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron. 2003;37:417–431. doi: 10.1016/s0896-6273(03)00034-5. [DOI] [PubMed] [Google Scholar]
  120. Morales J, Hiesinger PR, Schroeder AJ, Kume K, Verstreken P, Jackson FR, Nelson DL, Hassan BA. Drosophila fragile X protein, DFXR, regulates neuronal morphology and function in the brain. Neuron. 2002;34:961–972. doi: 10.1016/s0896-6273(02)00731-6. [DOI] [PubMed] [Google Scholar]
  121. Moult PR, Gladding CM, Sanderson TM, Fitzjohn SM, Bashir ZI, Molnar E, Collingridge GL. Tyrosine phosphatases regulate AMPA receptor trafficking during metabotropic glutamate receptor-mediated long-term depression. J Neurosci. 2006;26:2544–2554. doi: 10.1523/JNEUROSCI.4322-05.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Muddashetty RS, Kelic S, Gross C, Xu M, Bassell GJ. Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J Neurosci. 2007;27:5338–5348. doi: 10.1523/JNEUROSCI.0937-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. Musumeci SA, Hagerman RJ, Ferri R, Bosco P, Dalla Bernardina B, Tassinari CA, De Sarro GB, Elia M. Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia. 1999;40:1092–1099. doi: 10.1111/j.1528-1157.1999.tb00824.x. [DOI] [PubMed] [Google Scholar]
  124. Musumeci SA, Bosco P, Calabrese G, Bakker C, De Sarro GB, Elia M, Ferri R, Oostra BA. Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia. 2000;41:19–23. doi: 10.1111/j.1528-1157.2000.tb01499.x. [DOI] [PubMed] [Google Scholar]
  125. Nakamoto M, Nalavadi V, Epstein MP, Narayanan U, Bassell GJ, Warren ST. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc Natl Acad Sci U S A. 2007;104:15537–15542. doi: 10.1073/pnas.0707484104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  126. Napoli I, Mercaldo V, Boyl PP, Eleuteri B, Zalfa F, De Rubeis S, Di Marino D, Mohr E, Massimi M, Falconi M, Witke W, Costa-Mattioli M, Sonenberg N, Achsel T, Bagni C. The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell. 2008;134:1042–1054. doi: 10.1016/j.cell.2008.07.031. [DOI] [PubMed] [Google Scholar]
  127. Narayanan U, Nalavadi V, Nakamoto M, Pallas DC, Ceman S, Bassell GJ, Warren ST. FMRP phosphorylation reveals an immediate-early signaling pathway triggered by group I mGluR and mediated by PP2A. J Neurosci. 2007;27:14349–14357. doi: 10.1523/JNEUROSCI.2969-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. Narayanan U, Nalavadi V, Nakamoto M, Thomas G, Ceman S, Bassell GJ, Warren ST. S6K1 phosphorylates and regulates FMRP with the neuronal protein synthesis-dependent mTOR signaling cascade. J Biol Chem. 2008 doi: 10.1074/jbc.C800055200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  129. Nimchinsky EA, Oberlander AM, Svoboda K. Abnormal development of dendritic spines in FMR1 knockout mice. J Neurosci. 2001;21:5139–5146. doi: 10.1523/JNEUROSCI.21-14-05139.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Nosyreva ED, Huber KM. Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile x syndrome. J Neurophysiol. 2006;95:3291–3295. doi: 10.1152/jn.01316.2005. [DOI] [PubMed] [Google Scholar]
  131. O’Donnell WT, Warren ST. A decade of molecular studies of fragile X syndrome. Annu Rev Neurosci. 2002;25:315–338. doi: 10.1146/annurev.neuro.25.112701.142909. [DOI] [PubMed] [Google Scholar]
  132. Okabe S, Miwa A, Okado H. Spine formation and correlated assembly of presynaptic and postsynaptic molecules. J Neurosci. 2001;21:6105–6114. doi: 10.1523/JNEUROSCI.21-16-06105.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. Pan L, Broadie KS. Drosophila fragile X mental retardation protein and metabotropic glutamate receptor A convergently regulate the synaptic ratio of ionotropic glutamate receptor subclasses. J Neurosci. 2007;27:12378–12389. doi: 10.1523/JNEUROSCI.2970-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  134. Pan L, Zhang YQ, Woodruff E, Broadie K. The Drosophila fragile X gene negatively regulates neuronal elaboration and synaptic differentiation. Curr Biol. 2004;14:1863–1870. doi: 10.1016/j.cub.2004.09.085. [DOI] [PubMed] [Google Scholar]
  135. Pan L, Woodruff E, 3rd, Liang P, Broadie K. Mechanistic relationships between Drosophila fragile X mental retardation protein and metabotropic glutamate receptor A signaling. Mol Cell Neurosci. 2008 doi: 10.1016/j.mcn.2008.01.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. Paradee W, Melikian HE, Rasmussen DL, Kenneson A, Conn PJ, Warren ST. Fragile X mouse: strain effects of knockout phenotype and evidence suggesting deficient amygdala function. Neuroscience. 1999;94:185–192. doi: 10.1016/s0306-4522(99)00285-7. [DOI] [PubMed] [Google Scholar]
  137. Park S, Park JM, Kim S, Kim JA, Shepherd JD, Smith-Hicks CL, Chowdhury S, Kaufmann W, Kuhl D, Ryazanov AG, Huganir RL, Linden DJ, Worley PF. Elongation factor 2 and fragile X mental retardation protein control the dynamic translation of Arc/Arg3.1 essential for mGluR-LTD. Neuron. 2008;59:70–83. doi: 10.1016/j.neuron.2008.05.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Penagarikano O, Mulle JG, Warren ST. The Pathophysiology of Fragile X Syndrome. Annu Rev Genomics Hum Genet. 2007 doi: 10.1146/annurev.genom.8.080706.092249. [DOI] [PubMed] [Google Scholar]
  139. Pfeiffer BE, Huber KM. Fragile X mental retardation protein induces synapse loss through acute postsynaptic translational regulation. J Neurosci. 2007;27:3120–3130. doi: 10.1523/JNEUROSCI.0054-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  140. Plath N, et al. Arc/Arg3.1 is essential for the consolidation of synaptic plasticity and memories. Neuron. 2006;52:437–444. doi: 10.1016/j.neuron.2006.08.024. [DOI] [PubMed] [Google Scholar]
  141. Price TJ, Flores CM, Cervero F, Hargreaves KM. The RNA binding and transport proteins staufen and fragile X mental retardation protein are expressed by rat primary afferent neurons and localize to peripheral and central axons. Neuroscience. 2006;141:2107–2116. doi: 10.1016/j.neuroscience.2006.05.047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  142. Purpura DP. Dendritic spine “dysgenesis” and mental retardation. Science. 1974;186:1126–1128. doi: 10.1126/science.186.4169.1126. [DOI] [PubMed] [Google Scholar]
  143. Qin M, Kang J, Burlin TV, Jiang C, Smith CB. Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse. J Neurosci. 2005a;25:5087–5095. doi: 10.1523/JNEUROSCI.0093-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  144. Qin Y, Zhu Y, Baumgart JP, Stornetta RL, Seidenman K, Mack V, van Aelst L, Zhu JJ. State-dependent Ras signaling and AMPA receptor trafficking. Genes Dev. 2005b;19:2000–2015. doi: 10.1101/gad.342205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  145. Rakic P, Bourgeois JP, Eckenhoff MF, Zecevic N, Goldman-Rakic PS. Concurrent overproduction of synapses in diverse regions of the primate cerebral cortex. Science. 1986;232:232–235. doi: 10.1126/science.3952506. [DOI] [PubMed] [Google Scholar]
  146. Raymond CR, Thompson VL, Tate WP, Abraham WC. Metabotropic glutamate receptors trigger homosynaptic protein synthesis to prolong long-term potentiation. J Neurosci. 2000;20:969–976. doi: 10.1523/JNEUROSCI.20-03-00969.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  147. Reeve SP, Bassetto L, Genova GK, Kleyner Y, Leyssen M, Jackson FR, Hassan BA. The Drosophila fragile X mental retardation protein controls actin dynamics by directly regulating profilin in the brain. Curr Biol. 2005;15:1156–1163. doi: 10.1016/j.cub.2005.05.050. [DOI] [PubMed] [Google Scholar]
  148. Restivo L, Ferrari F, Passino E, Sgobio C, Bock J, Oostra BA, Bagni C, Ammassari-Teule M. Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc Natl Acad Sci U S A. 2005;102:11557–11562. doi: 10.1073/pnas.0504984102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  149. Rial Verde EM, Lee-Osbourne J, Worley PF, Malinow R, Cline HT. Increased expression of the immediate-early gene arc/arg3.1 reduces AMPA receptor-mediated synaptic transmission. Neuron. 2006;52:461–474. doi: 10.1016/j.neuron.2006.09.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  150. Ronesi JA, Huber KM. Metabotropic glutamate receptors and fragile x mental retardation protein: partners in translational regulation at the synapse. Sci Signal. 2008a;1:pe6. doi: 10.1126/stke.15pe6. [DOI] [PubMed] [Google Scholar]
  151. Ronesi JA, Huber KM. Homer interactions are necessary for metabotropic glutamate receptor-induced long-term depression and translational activation. J Neurosci. 2008b;28:543–547. doi: 10.1523/JNEUROSCI.5019-07.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  152. Rudelli RD, Brown WT, Wisniewski K, Jenkins EC, Laure-Kamionowska M, Connell F, Wisniewski HM. Adult fragile X syndrome. Clinico-neuropathologic findings. Acta Neuropathol (Berl) 1985;67:289–295. doi: 10.1007/BF00687814. [DOI] [PubMed] [Google Scholar]
  153. Schenck A, Bardoni B, Moro A, Bagni C, Mandel JL. A highly conserved protein family interacting with the fragile X mental retardation protein (FMRP) and displaying selective interactions with FMRP-related proteins FXR1P and FXR2P. Proc Natl Acad Sci U S A. 2001;98:8844–8849. doi: 10.1073/pnas.151231598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  154. Schenck A, Bardoni B, Langmann C, Harden N, Mandel JL, Giangrande A. CYFIP/Sra-1 controls neuronal connectivity in Drosophila and links the Rac1 GTPase pathway to the fragile X protein. Neuron. 2003;38:887–898. doi: 10.1016/s0896-6273(03)00354-4. [DOI] [PubMed] [Google Scholar]
  155. Selby L, Zhang C, Sun QQ. Major defects in neocortical GABAergic inhibitory circuits in mice lacking the fragile X mental retardation protein. Neurosci Lett. 2007;412:227–232. doi: 10.1016/j.neulet.2006.11.062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  156. Seog DH. Glutamate receptor-interacting protein 1 protein binds to the microtubule-associated protein. Biosci Biotechnol Biochem. 2004;68:1808–1810. doi: 10.1271/bbb.68.1808. [DOI] [PubMed] [Google Scholar]
  157. Siomi H, Siomi MC, Nussbaum RL, Dreyfuss G. The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell. 1993;74:291–298. doi: 10.1016/0092-8674(93)90420-u. [DOI] [PubMed] [Google Scholar]
  158. Snyder EM, Philpot BD, Huber KM, Dong X, Fallon JR, Bear MF. Internalization of ionotropic glutamate receptors in response to mGluR activation. Nat Neurosci. 2001;4:1079–1085. doi: 10.1038/nn746. [DOI] [PubMed] [Google Scholar]
  159. Spencer CM, Alekseyenko O, Serysheva E, Yuva-Paylor LA, Paylor R. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav. 2005;4:420–430. doi: 10.1111/j.1601-183X.2005.00123.x. [DOI] [PubMed] [Google Scholar]
  160. Stefani G, Fraser CE, Darnell JC, Darnell RB. Fragile X mental retardation protein is associated with translating polyribosomes in neuronal cells. J Neurosci. 2004;24:7272–7276. doi: 10.1523/JNEUROSCI.2306-04.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  161. Sung YJ, Conti J, Currie JR, Brown WT, Denman RB. RNAs that interact with the fragile X syndrome RNA binding protein FMRP. Biochem Biophys Res Commun. 2000;275:973–980. doi: 10.1006/bbrc.2000.3405. [DOI] [PubMed] [Google Scholar]
  162. Sung YJ, Dolzhanskaya N, Nolin SL, Brown T, Currie JR, Denman RB. The fragile X mental retardation protein FMRP binds elongation factor 1A mRNA and negatively regulates its translation in vivo. J Biol Chem. 2003;278:15669–15678. doi: 10.1074/jbc.M211117200. [DOI] [PubMed] [Google Scholar]
  163. Tamanini F, Meijer N, Verheij C, Willems PJ, Galjaard H, Oostra BA, Hoogeveen AT. FMRP is associated to the ribosomes via RNA. Hum Mol Genet. 1996;5:809–813. doi: 10.1093/hmg/5.6.809. [DOI] [PubMed] [Google Scholar]
  164. Tassone F, Hagerman RJ, Ikle DN, Dyer PN, Lampe M, Willemsen R, Oostra BA, Taylor AK. FMRP expression as a potential prognostic indicator in fragile X syndrome. Am J Med Genet. 1999;84:250–261. [PubMed] [Google Scholar]
  165. Tavazoie SF, Alvarez VA, Ridenour DA, Kwiatkowski DJ, Sabatini BL. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat Neurosci. 2005;8:1727–1734. doi: 10.1038/nn1566. [DOI] [PubMed] [Google Scholar]
  166. Tessier CR, Broadie K. Drosophila fragile X mental retardation protein developmentally regulates activity-dependent axon pruning. Development. 2008;135:1547–1557. doi: 10.1242/dev.015867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  167. Todd PK, Mack KJ, Malter JS. The fragile X mental retardation protein is required for type-I metabotropic glutamate receptor-dependent translation of PSD-95. Proc Natl Acad Sci U S A. 2003;100:14374–14378. doi: 10.1073/pnas.2336265100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  168. Tzingounis AV, Nicoll RA. Arc/Arg3.1: linking gene expression to synaptic plasticity and memory. Neuron. 2006;52:403–407. doi: 10.1016/j.neuron.2006.10.016. [DOI] [PubMed] [Google Scholar]
  169. Vanderklish PW, Edelman GM. Dendritic spines elongate after stimulation of group 1 metabotropic glutamate receptors in cultured hippocampal neurons. Proc Natl Acad Sci U S A. 2002;99:1639–1644. doi: 10.1073/pnas.032681099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  170. Vasudevan S, Steitz JA. AU-rich-element-mediated upregulation of translation by FXR1 and Argonaute 2. Cell. 2007;128:1105–1118. doi: 10.1016/j.cell.2007.01.038. [DOI] [PMC free article] [PubMed] [Google Scholar]
  171. Volk LJ, Pfeiffer BE, Gibson JR, Huber KM. Multiple Gq-coupled receptors converge on a common protein synthesis-dependent long-term depression that is affected in fragile X syndrome mental retardation. J Neurosci. 2007;27:11624–11634. doi: 10.1523/JNEUROSCI.2266-07.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  172. Wang H, Dictenberg J, Ku L, Li W, Bassell GJ, Feng Y. Dynamic Association of the Fragile X Mental Retardation Protein as an mRNP between Microtubules and Polyribosomes. Mol Biol Cell. 2007 doi: 10.1091/mbc.E07-06-0583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  173. Wang H, Wu LJ, Kim SS, Lee FJ, Gong B, Toyoda H, Ren M, Shang YZ, Xu H, Liu F, Zhao MG, Zhuo M. FMRP acts as a key messenger for dopamine modulation in the forebrain. Neuron. 2008;59:634–647. doi: 10.1016/j.neuron.2008.06.027. [DOI] [PubMed] [Google Scholar]
  174. Waung MW, Pfeiffer BE, Nosyreva ED, Ronesi JA, Huber KM. Rapid translation of Arc/Arg3.1 selectively mediates mGluR-dependent LTD through persistent increases in AMPAR endocytosis rate. Neuron. 2008;59:84–97. doi: 10.1016/j.neuron.2008.05.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  175. Weiler IJ, Greenough WT. Metabotropic glutamate receptors trigger postsynaptic protein synthesis. Proc Natl Acad Sci U S A. 1993;90:7168–7171. doi: 10.1073/pnas.90.15.7168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  176. Weiler IJ, Greenough WT. Synaptic synthesis of the Fragile X protein: possible involvement in synapse maturation and elimination. Am J Med Genet. 1999;83:248–252. doi: 10.1002/(sici)1096-8628(19990402)83:4<248::aid-ajmg3>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  177. Weiler IJ, Spangler CC, Klintsova AY, Grossman AW, Kim SH, Bertaina-Anglade V, Khaliq H, de Vries FE, Lambers FA, Hatia F, Base CK, Greenough WT. Fragile X mental retardation protein is necessary for neurotransmitter-activated protein translation at synapses. Proc Natl Acad Sci U S A. 2004;101:17504–17509. doi: 10.1073/pnas.0407533101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  178. Wells DG. RNA-binding proteins: a lesson in repression. J Neurosci. 2006;26:7135–7138. doi: 10.1523/JNEUROSCI.1795-06.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  179. Westmark CJ, Malter JS. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol. 2007;5:e52. doi: 10.1371/journal.pbio.0050052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  180. Wilson BM, Cox CL. Absence of metabotropic glutamate receptor-mediated plasticity in the neocortex of fragile X mice. Proc Natl Acad Sci U S A. 2007;104:2454–2459. doi: 10.1073/pnas.0610875104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  181. Wisniewski KE, Segan SM, Miezejeski CM, Sersen EA, Rudelli RD. The Fra(X) syndrome: neurological, electrophysiological, and neuropathological abnormalities. Am J Med Genet. 1991;38:476–480. doi: 10.1002/ajmg.1320380267. [DOI] [PubMed] [Google Scholar]
  182. Zalfa F, Giorgi M, Primerano B, Moro A, Di Penta A, Reis S, Oostra B, Bagni C. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell. 2003;112:317–327. doi: 10.1016/s0092-8674(03)00079-5. [DOI] [PubMed] [Google Scholar]
  183. Zalfa F, Adinolfi S, Napoli I, Kuhn-Holsken E, Urlaub H, Achsel T, Pastore A, Bagni C. Fragile X mental retardation protein (FMRP) binds specifically to the brain cytoplasmic RNAs BC1/BC200 via a novel RNA-binding motif. J Biol Chem. 2005;280:33403–33410. doi: 10.1074/jbc.M504286200. [DOI] [PubMed] [Google Scholar]
  184. Zalfa F, Eleuteri B, Dickson KS, Mercaldo V, De Rubeis S, di Penta A, Tabolacci E, Chiurazzi P, Neri G, Grant SG, Bagni C. A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat Neurosci. 2007;10:578–587. doi: 10.1038/nn1893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  185. Zarnescu DC, Shan G, Warren ST, Jin P. Come FLY with us: toward understanding fragile X syndrome. Genes Brain Behav. 2005;4:385–392. doi: 10.1111/j.1601-183X.2005.00136.x. [DOI] [PubMed] [Google Scholar]
  186. Zhang Y, Venkitaramani DV, Gladding CM, Kurup P, Molnar E, Collingridge GL, Lombroso PJ. The tyrosine phosphatase STEP mediates AMPA receptor endocytosis after metabotropic glutamate receptor stimulation. J Neurosci. 2008;28:10561–10566. doi: 10.1523/JNEUROSCI.2666-08.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  187. Zhang YQ, Broadie K. Fathoming fragile X in fruit flies. Trends Genet. 2005;21:37–45. doi: 10.1016/j.tig.2004.11.003. [DOI] [PubMed] [Google Scholar]
  188. Zhang YQ, Bailey AM, Matthies HJ, Renden RB, Smith MA, Speese SD, Rubin GM, Broadie K. Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. Cell. 2001;107:591–603. doi: 10.1016/s0092-8674(01)00589-x. [DOI] [PubMed] [Google Scholar]
  189. Zhao MG, Toyoda H, Ko SW, Ding HK, Wu LJ, Zhuo M. Deficits in trace fear memory and long-term potentiation in a mouse model for fragile X syndrome. J Neurosci. 2005;25:7385–7392. doi: 10.1523/JNEUROSCI.1520-05.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  190. Zhu JJ, Qin Y, Zhao M, Van Aelst L, Malinow R. Ras and Rap control AMPA receptor trafficking during synaptic plasticity. Cell. 2002;110:443–455. doi: 10.1016/s0092-8674(02)00897-8. [DOI] [PubMed] [Google Scholar]
  191. Zuo Y, Lin A, Chang P, Gan WB. Development of long-term dendritic spine stability in diverse regions of cerebral cortex. Neuron. 2005a;46:181–189. doi: 10.1016/j.neuron.2005.04.001. [DOI] [PubMed] [Google Scholar]
  192. Zuo Y, Yang G, Kwon E, Gan WB. Long-term sensory deprivation prevents dendritic spine loss in primary somatosensory cortex. Nature. 2005b;436:261–265. doi: 10.1038/nature03715. [DOI] [PubMed] [Google Scholar]

RESOURCES